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Chaptcl'l 
GENERAL INTRODUCTION 
F.P. Vleggaar 
Immullocholangitis is a collective for chronic inflammatory disorders affecting the 
biliary tree, presumably with an autoimmune-mediated pathogenesis. Destruction and 
distortion of bile ducts, leading to impaired bile flmv, are key features of 
immunocholangitis. In general, primary biliary cirrhosis (PBC) and primary sclerosing 
cholangitis (PSC) are considered to be the main diseases of immunochoiangitis. 
PBC, a chronic cholestatic liver disease, is one of the most common vanishing bile 
duct disorders (I). Gradual loss of interlobular and septal bile ducts, histologically 
described as chronic non-suppurative destructive cholangitis (2), leads to chronic 
cholestasis, fibrosis and biliary cirrhosis which may ultimately cause liver failure, 
necessitating transplantation (3). Since 1988, PBC has been the third leading indication for 
liver transplantation in Europe (European Liver Transplant Association (ELTA) 
registration). 
Typical symptoms of patients with PBe are pmritus, fatigue, arthralgia and dryness of 
the eyes and mouth (3). A large proportion of patients, especially those with early stage 
PBC are however often asymptomatic. Physical examination may reveal jaundice, scratch 
marks, xanthelasma and xanthoma, in particular in the event of marked cholestasis. 
PBC is a relatively rare disorder in comparison with chronic viral hepatitis and 
alcoholic liver disease. It affects primarily middle-aged (40-60 years) women (male:female 
ratio 1:9). In the 1970's, reported prevalences ranged from only 18 to 54 cases per one 
million inhabitants (4-6). Since then, substantially higher prevalence rates have been 
reported (6, 7). Recent studies in Wales (8) and the Newcastle area (9) revealed a 
prevalence of 200-250 PBC patients per one million inhabitants in 1994, suggesting a more 
than tenfold increase in less than 20 years! \Vhether these data reflect a true increase in the 
number of cases is uncertain. The development of more sophisticated epidemiological case 
fmding methods, increased awareness of PBC as a possible cause of chronic liver disease 
and routine assessment of serum liver tests for medical examinations (Le. for insurance) 
may all have contributed to the identification of more, in particular asymptomatic, cases. 
Moreover, the diagnosis of asymptomatic subjects might result in higher prevalence rates 
because of longer survival. 
PSC is a cryptogenic chronic cholestatic liver disease characterised by progressive 
strichlring and obliteration of intrahepatic andlor extrahepatic bile ducts (10), leading to 
fibrosis and biliary cirrhosis which may cause hepatic decompensation. Since 1988, PSC 
has been the sixth leading indication for transplantation (ELTA registration). The signs and 
symptoms of PSC resemble those of PEe. 
6 
PSC is regarded as an even more rare disease than PBC, but reliable epidemiological 
data on prevalence and incidence are lacking. Data from Sweden suggest a prevalence of 
60-80 patients per one million inhabitants (II). There is a strong association with 
inflammatory bowel disease (IBD). It has been found that approximately four percent of 
patients with IBD have concomitant PSC (12). Conversely, 50-70% of patients \vith PSC 
also have IBD (13, 14). PSC has a male predominance (male:female ratio 2: 1). The median 
age at diagnosis is 35 years. 
Classification of innnunocholangitis 
Plimm), hi/ial)' cinilOsis and its vwiants 
The diagnosis of PBC is based 011 the presence of serum antimitochondrial antibodies 
(AMA), serum liver tests indicating cholestasis and a liver biopsy showing chronic non-
suppurative destructive cholangitis (15). In a small minority of cases (5-10%), the last two 
criteria are present but serological testing for AMA is negative. These patients have so-
called AM A-negative PBe (16), An elevated IgM level, quite common in PBe patients, 
further supports this diagnosis. 
As a rule PBC and autoimmune hepatitis CAJH) are generally easily differentiated on 
the basis of clinical, biochemical, serological and histological findings. In a minority of 
cases, however, PBC and AIH may develop either simultaneously or consecutively (17, 
18). Recognition of tllis variant of PBC, the PBC-AIH overlap syndrome, is not only 
important from the standpoint of classification, since it can have therapeutic implications: 
patients with this disorder may beneHt from immunosuppressive therapy (19). PBC-AIH 
overlap was found in 9% of PBC patients in a study pelformed in France (19). 
The histological patterns of PBC have been divided into four consecutive stages (2). 
PBC stage I stands for portal hepatitis with little or no interface hepatitis, stage II is 
periportal hepatitis with interface hepatitis and ductular proliferation, stage TIl is 
characterized by fibrous septa or bridging necrosis and stage IV is biliary cilThosis. In 
general, jaundice is only encountered in the cirrhotic stage (20), probably as a consequence 
of both hepatocellular insufficiency and bile duct loss. Jaundice in non-cirrhotic PBC is 
rare. In contrast to what is observed in patients with the idiopathic adulthood ductopenia 
syndrome (21), it appears that the degree of intrahepatic bile duct loss is usually not severe 
enough to cause jaundice. In chapter 2, we report on a subgroup of PBC patients suffering 
from severe cholestatic, icteric disease for which no causative extrahepatic or intrahepatic 
factors other than profound ductopenia could be identified. These cases and a large group 
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of equally non-cinhotic PBe patients were included in a histomorphologicai study to 
define the dllctopenia-fibrosis relationship and to test the hypothesis that these patients 
exhibit extreme paucity of bile ducts in relation to the amount of fibrosis. 
Sclemsillg cholangitis alld ils vwiallfs 
Endoscopic retrograde cholangiography (ERC) is a key step in the diagnostic 
evaluation of potential PSC patients and remains the "gold standard" for diagnosis (22). 
Typical findings are fibrosis and sclerosis of the biliary tree with localized or multi focal 
strictures and intermediate segments of normal, diverticulum-like outpouchings or ectatic 
ducts (23). 
The vast majority of patients with PSC show extrahepatic or intrahepatic biliary 
abnormalities on cholangiography. In a small minority of patients with IBD and elevated 
cholestatic semlll liver tests, cholangiography shows a normal biliary tree whereas liver 
biopsy reveals perichoiangiolal' layered (onion-skin) fibrosis, which is a typical 
histological feature of PSC. This disorder is regarded as a variant of PSC, known as small-
duct PSC (24). 
Another variant of PSC is the PSC-AIH overlap syndrome (25, 26). In addition to the 
cholangiographic and clinical characteristics of PSC, patients with tllis overlap syndrome 
have markedly elevated semm transaminase and immunoglobulin G or ganunaglobulin 
levels, in combination with Sel1Ull autoantibodies, such as antinuclear antibodies and 
smooth muscle antibodies, and liver histological abnormalities compatible with AnI. The 
therapeutic response of at least the AIH-component of this disorder to corticosteroids can 
be excellent. Therefore, clinicians should be well aware of this syndrome, wllich may be 
more common than previously thought (chapter 3). 
Another variant of sclerosing cholangitis occurs primarily in middle-aged men without 
IBD, usually presenting with jaundice and weight loss. Imaging studies demonstrate focal 
or diffuse enlargement of the pancreas, strongly suggestive of malignancy. Diabetes 
mellitus and exocrine pancreatic insufficiency may also be found. Cholangiography reveals 
the pattern of sclerosing cholangitis. A series of 10 patients with this particular syndrome, 
so-called "sclerosing pancreato-cholangitis", is described in chapler 4, in wllich the 
question is posed whether this disease is just an atypical form of ordinary PSC. 
It is important to remember that the biliary system possesses a rather linlited reportoire 
of responses to a variety of pathological processes and that the radiological appearance of 
diffuse stricturing and segmental dilatation of the biliary system may be encountered in 
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association with a broad array of local and systemic diseases (27). Various 
immunodeficiency states, i.e. AIDS, may facilitate opporhmistic infection of the biliary 
tree, resulting in sclerosing cholangitis (28). Furthermore, toxic (29) and ischaemic (30) 
damage to the biliary system may also result in the development of sclerosing cholangitis. 
In chapter 5 a group of patients with sclerosing cholangitis due to portal vein thrombosis is 
described. 
Pl'ognosis of illnllullocholangitis 
The determination of a patient's prognosis is an important tool for clinical decision-
making. Timing of liver transplantation and selection of patients for the evaluation of new 
drugs in clinical trials are two examples of important decisions which primarily depend on 
the patient's future prospects. 
PlimalY hilimy cinflosis 
It is generally known that in some patients PBe will follow a fairly benign course over 
a period of lUore than 20 years without developing into cirrhosis, whereas in others a 
progressive course will necessitate transplantation within less than 10 years after diagnosis 
of PBC. Tltis variable clinical course clearly illustrates the need for a prognostic tool. 
Mathematical prognostic models, such as the Mayo model (31), use variables that may 
change in time, such as serum bilimbin and albumin levels, to predict the clinical course 
and consequently the tinting of liver transplantation. However, in the early stages of PBC, 
when bilirubin and albumin levels are normal, these models cannot predict whether the 
disease will follow a relatively benign or a progressive course. 
Since the relationsitip between PBC and AMA is close, many studies have focused on 
the correlation of various aspects of AMA and prognosis. Previous studies found no 
evidence that AMA titres (32) or the absence of AMA is related to disease progression 
(33). Four MIA-subtypes have been found to be quite specific for PBe. Prognostic value 
has been attributed to these AMA-subtypes, which can be linked to the presence of allti-
M2, -M4, -M8 and -M9 antibodies (34-37). German PBe patients with semm anti-M4 
andlor anti-M8 antibodies were reported to have a progressive course of the disease, 
leading to cirrhosis and hepatic decompensation, whereas the course in patients without 
anti-M4 and anti-M8 antibodies was found to be non-progressive for at least 10 years (38-
41). In chapter 6, we aimed to continl1 the prognostic value of AMA-subtypes in a 
heterogeneous population of Dutch PBC patients. 
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Plimm), sclemsing cholangitis 
PSC is a progressive disease with an estimated median duration of transplantation-free 
survival of approximately 12 years (42-44). As in many chronic cholestatic liver diseases, 
the course of the disease may be characterized by development of biliary cirrhosis, 
eventually resulting in hepatic decompensation. A number of complications of PSC, 
however, are quite specific to the disease. The development of dominant bile duct 
strictures causing cholestatic jaundice is a characteristic feature of PSC (45, 46). 
Furthermore, PSC patients are more prone to bacterial cholangitis (10) due to the 
malformed biliary tree. Cholangiocarcinoma is the most feared complication of the disease, 
since the 2-year survival rate for PSC patients with tltis malignancy is below 20% (47). 
Another potentially life-threatening problem in PSC is the development of colorectal 
cancer, as the vast majority of patients also have long-standing IBD. The risks and clinical 
impact of these complications are poorly documented. The study described in chapter 7 
was conducted to evaluate the risks of dominant bile duct strictures, suppurative 
cholangitis, cholangiocarcinoma and colorectal cancer and to define the influence of the 
first two complications together with the baseline patient characteristics on transplantation-
free survival in a cohort of PSC patients. Furthermore, we evaluated whether the new 
Mayo PSC prognostic model (48) fits our patient population. 
Treatment of illllllullochoiallgitis 
Plimm), hillm)' Gin/lOsts 
Since the cause of PBC is unknown, the scientific search for medical treatment has 
been characterised by a trial-and-error approach. Consequently, H large variety of agents 
have been tested as potential therapies for patients \vith PBC. Most of them were 
ineffective or had serious side etTects when studied in well-designed clinical trials (49-53). 
Until recently, ursodeoxycholic acid (UDCA) was without doubt considered to be one 
of the few exceptions. A fairly large number of controlled trials demonstrated convincingly 
that tillS treatment improves serum liver tests, including bilirubin level (54-63). Although 
improvement in (liver transplantation-free) survival should be the main end-point of the 
evaluation of new treatments for PBC, none of these trials was specifically designed to 
assess the effects of UDCA therapy on mortality. Therefore, meta-analysis of individual 
patient data (n=548) from three of the larger trials was performed (64). A significant 
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improvement in survival without liver transplantation (but not of overall survival) was 
demonstrated by this combined analysis. 
In addition, recent studies have demonstrated convincingly that UDCA slows 
progression of the disease towards its irreversible terminal phase. First, it should be 
emphasized that survival of UDCA-treatcd patients is bettcr than that predicted by the 
Mayo-model of survival (65). Secondly, UDCA therapy retards histological progression 
(63) and delays the onset of cirrhosis, according to long-tenn stndies (66). 
As a result, the use of UDCA as standard treatment for PBC seemed to be established. 
Two rccently published meta-analyses, however, have cast a reasonable doubt on the 
benefit of UDCA therapy for PBC (67, 68). Surprisingly, both studies, comprising more 
than 1200 patients treated in randomised clinical trials, found no difference between 
UDCA and placebo treatment with respect to the incidence of death, liver-related death, 
liver transplantation, death or liver transplantation, and the development of complications 
of chronic liver disease. It should be noted that neither meta-analysis was based on the 
original individual patient data, only OIl published data. Furthermore, not all trials included 
in these analyses used the proposed optimum dosage schedule of 13-15 mg/kg/day. For the 
higher doses it was shown that these regimens provided the optimal enrichment in biliary 
UDCA as well as the most significant changes in liver function tests (69). 
Apal1 from the present uncet1ainty about whether UDCA therapy retards the course of 
PBC, it is clear that this dlUg is certainly not potent enough to halt progrcssion of the 
disease and that a second therapeutic modality is needed. Additional or alternative 
treatments thercfore have to be developed. Assuming that PBC is an immune disease, 
addition of immunosuppressive drugs to UDCA was an obvious next step. So far, three 
randomised controlled trials have shown that combined UDCA-corticosteroid treatment 
exerts more favourable effects on pruritus, semm liver tests and histological disease 
activity than UDCA-monotherapy (70-72). Since these studies should be considered as 
pilot studies because of the limited duration of treatment and the small numbers of patients, 
it remains speculative whether prolonged combined bile acid and immunosuppressive 
treatment has a beneficial effect on histological and clinical progression and mortality. 
Plimmy sc/emsing cholangitis 
In contrast to PBC, the number of randomised controlled trials 011 PSC is fairly 
limited. Penicillamine (73), methotrexate (74) and colchicine (75) were all found to be 
ineffective. The first placebo-controlled pilot study on UDCA in PSC showed significant 
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imprm'ement in senUll liver tests and some histological feahlres after one year of treatment 
(76). Lindor et al. performed a placebo-controlled trial with UDCA among 105 PSC 
patients. After a median period of two years, biochemical improvement but no clinical or 
histological benefit could be documented (77). In this respect it should be noted that the 
number of patients and the median duration of follow-up were limited in comparison to 
observations in PBC. 
Recently, we performed a randomised controIled trial with UDCA-treated PSC 
patients to evaluate the additional effect of oral prednisone and budesonide therapy. 
Budesonide is a corticosteroid with high first pass liver clearance which, in theory, allows 
higher concentrations of active drug to be delivered to the biliary tree (cliapter 8). 
The clinical, biochemical and, most importantly, cholangiographic response to open-
label corticosteroid treatment in patients with sclerosing pancreato-cholangitis is described 
in cliapter 9. 
In vie,v of the results of two case-control studies suggesting that cigarette smoking 
protects against the development of PSC (78, 79), we wondered \vhether nicotine patch 
treatment could treat more than smoking addiction. \Ve therefore performed a double-blind 
cross-over pilot trial to evaluate the efficacy and safety of transdennal nicotine treatment 
(Chapter 10). 
In the subgroup of patients with 'large-duct' PSC, regular endoscopic treatment may 
be an alternative to pharmacological treatment. Stiehl et aJ. petfonned an open prospective 
study of frequent endoscopic dilatation of mqior bile duct strictures. They reported that 
transplantation-free survival was improved compared to survival predicted by the Mayo 
model (80). Tllis is an interesting observation which needs to be shldied within the context 
of a randomised controlled trial, wWch remains the gold standard for testing the efficacy of 
new therapies. 
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Submitted 
Abstl'act 
The clinical and pathological fIndings on four females with primary bilimy 
cirrhosis with an unusual and hitherto not well recognized course arc reported. Patients 
suffered severe pmritns and weight loss with progressive icteric cholestasis which did not 
respond to snch treatments as ursodeoxycholic acid and immunosuppressives. In all cases 
liver histology revealed marked bile duct loss without, however, significant fibrosis or 
cilThosis. Further diagnostic studies and repeat biopsies confirmed the absence of liver 
cilThosis as well as other potential causes of hyperbililUbinemia. Comparison of the 
fibrosis-ductopenia relationship for Ollr cases with that for a group of 10 I non-cirrhotic 
PBC patients indicated that in the fonner the severity of bile duct loss relative to the 
amount of fibrosis was significantly higher. The proportion of portal triads containing an 
interlobular bile duct was 3, 4, 6 and 10% compared to 45% (median; range 8.3 - 100%) 
for controls (p<O.OOI). Three patients received a liver transplant 6-7 years after the first 
manifestation of PBC because of progressive cholestasis, refractory pruritus and weight 
loss while the fourth patient is considering this option. In one case cirrhosis had developed 
at the time of transplantation while the others still had non-cirrhotic disease. These cases 
suggest that cholestatic jaundice in non-cirrhotic PBC may be secondary to extensive 
'premature' or accelerated intrahepatic bile duct loss. Although the extent of fibrosis may 
be limited initially, progression to cirrhosis appears to be inevitable in the long run. 
Despite intact protein synthesis and absence of cirrhotic complications, liver 
transplantation in the pre-cinhotic stage for preventing malnutrition and improve quality of 
life should be considered for these patients. 
Introduction 
Primary biliary cirrhosis (PBe) is a vanishing bile duct disorder (I) of a highly 
variable, albeit slowly progressive, nature. Imm.unologically mediated destI1lction of 
interlobular and septal bile ducts, resulting in bile duct loss or ductopenia, is considered to 
be one of the main pathophysiological events leading ultimately to liver fibrosis and biliary 
cirrhosis (2, 3). The histologic appearances have been divided into four stages, the last 
(stage IV) representing true cirrhosis (4). In general, jaundice is only encountered in the 
cirrhotic stage (5), probably as a consequence of both hepatocellular insll111ciency and bile 
duct loss. 
Jaundice in non-cirrhotic PBC is rare. In contrast to what is observed, for example, in 
the idiopathic adulthood ductopenia syndrome (6), it appears that the degree of intrahepatic 
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bile duct loss usually is not severe enough to cause jaundice. Various - mainly extrahepatic 
- factors not specifically related to PBe, including hyperthyroidism (7), malignant 
lymphoma (8, 9), liver metastases, certain dmgs (10), hemolysis (11, 12), concomitant 
autoimmune hepatitis flares (13) and major bile duct obstruction, can cause jaundice in 
non-cirrhotic PBe. 
\Ve report here on a subgroup of PBC patients suffering from severe cholestatic, icteric 
disease for whom no causative extrahepatic or intrahepatic factors other than profound 
ductopenia could be identified. Remarkably, this was not associated with histologic 
evidence of cirrhosis or substantial fibrosis. A histomorphological study of these cases and 
a large group of non-cinhotic PBC patients \vas performed to define the ductopenia-
fibrosis relationship and to test the hypothesis that our cases exhibited extreme paucity of 
bile ducts in relation to the amount of fibrosis. 
Cases 
Case 1 
In 1994, a 39-year-old Chinese woman presented with fatigue, pmritus and jaundice. 
Her previous medical history was unremarkable. There was no history of either alcohol or 
drug abuse or familial liver problems. Laboratory investigations showed cholestatic serum 
liver values (Table I), elevated IgM .Ievels aud an antimitochondrial antibody (AMA) titer 
of I: 10240. Other etiological studies for viral hepatitis, hemochromatosis, alpha-l-
antitrypsin deficiency and \Vilsou's disease were negative. A liver biopsy revealed severe 
ductopenia (Table I) and llon-cilThotic (stage II) PBe. Subsequent treatment with 
ursodeoxycholic acid (UDCA) and later with prednisone and azathioprine did not result in 
improvements in symptoms, serum bilimbin level or other laboratory parameters. Four 
years later a second biopsy was taken. At that time the senUll bilimbin level was 103 
~HllOl/l. Histologic examination showed two bile ducts in a total of 26 portal tracts. The 
degree of fibrosis had increased significantly and beginning nodularity of the liver 
parenchyma was noted (PBe stage Ill). At present, she is considering the possibility of 
liver transplantation. 
ease 2 
In 1992, a previously healthy 38-year-old Caucasian woman presented with pruritus 
and fatigue. A diagnosis of PBC was made on the basis of a positive test for AMA (titer 
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I: 10240), the cholestatic serum liver profile (bilirubin 34 [lmolll), elevated IgM levels and 
characteristic histology. Other etiological studies for viral hepatitis, hemochromatosis, 
alpha-I-antitrypsin deficiency and ·Wilson's disease were negative. UDCA therapy ,vas 
instituted but did not result in any improvement in the sennn liver tests. Treatment with 
unti-pruritics such as cholestyramine, rifampicin. naItrexone and oxazepam was 
unsuccessful. In 1997, combined prednisone and azathioprine treatment was given for 
three months without amelioration of complaints. One year later she was referred to the 
University Hospital Rotterdam. Jaundice (bilirubin: 77 ~l1nol/l) and marked cholestatic 
SClUlll liver values were found. Histologic examination of the liver revealed showed non-
cilThotic stage I PBC. In one out of 18 portal tracts one bile duct could be identified (Table 
I). Severe pruritus and progressive weight loss (13 kg in three years) were the main 
indications for performing liver transplantation eighteen months later. Histologic 
examination of a biopsy specimen of the liver explant showed PBC stage I with five intact 
bile ducts in 32 portal tracts. 
Case 3 
In 1990, a 38-year-old Caucasian woman presented with pruritus and arthralgia. Her 
previous medical history was unremarkable. On the basis of cholestatic serum liver values, 
elevated serum IgM levels, positive Ai\1A serology and the liver biopsy findings a 
diagnosis of PBC (stage I-II) was made. Other etiological studies for viral and metabolic 
liver disorders were negative. Treatment with UDCA and prednisone did liot l'csllit in 
evident symptomatic or biochemical improvements. Treatments with anti-pmritics such as 
cholestyramine, rifampicin and naltrexolle was unsuccessful. In 1995, the senUll bilirubin 
levels increased to over 150 ,.unol/1. Severe pruritus and fatigue persisted. A second liver 
biospy demonstrated non-cirrhotic, stage I-II PBC (Table I). Laparoscopy, abdominal 
ultrasonography and upper gastrointestinal endoscopy showed no evidence of cirrhosis or 
portal hypertension. Pruritus persisted and the weight loss was 7 kg when she received a 
transplant in 1997. The explant showed biliary cirrhosis (PBe stage IV). 
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Case 4 
In 1993, this 47-year-old Caucasian woman was diagnosed with of AMA-negative 
PBC. The diagnosis was based on serum liver tests indicating cholestasis, elevated senUll 
IgM levels and a liver biopsy showing chronic non-suppurative destmctive cholangitis 
with some portal granulomas. Other etiological studies for viral hepatitis. 
hemochromatosis, alpha-I-antitrypsin deficiency and \Vilson's disease were negative. 
Ursodeoxycholic acid treatment resulted in aggravation of the pruritus. Subsequently, 
severe pruritus persisted and failed to respond to choicstyramine, rifampicin and 
naltrexone. Furthermore, combination treatment with prednisone and azathioprine was 
given for one year without any symptomatic or biochemical improvement. Shortly after 
prednisone was discontinued severe jaundice (bilirubin: 129 1111101/1) with aggravating 
pruritus developed. Periocular and palmar xanthomatous skin abnormalities occUlTed and 
her bodyweight decreased from 85 to 55 kg within a period of one year. In 1999 liver 
transplantation was pelformed. The liver explant showed non-cinhotic, stage II-Ill PBe 
with striking bile duct loss (Table I). 
I'atients and methods 
The clinical, biochemical and histologic findings for our cases suggested that in these 
patients the course of the disease deviated from the 'normal' course. Most strikingly, the 
extent of bile duct loss seemed to be excessive in relation to the amount of fibrosis. To 
substantiate this impression, the quantified histologic findings on our patients were 
compared with those for a group of 101 consecutive, untreated PBe patients with non-
cirrhotic histology. This population was collected between 1990 and 1998 during a 
prospective cohort study of PBe in the Netherlands (14). Total serum bilirubin levels in 
this group were lower than 23 Ilmolll at the tiIlle of liver biopsy. In both our cases and the 
reference population liver specimens were obtained percutaneously using tm-cut or 
Menghini 14-16 Gauge needles. Biopsies were fixed in formalin and processed routinely 
into paraffin blocks. Sections were stained with hematoxylin and eosin as well as anti-
cytokeratill-19 antibodies. 
The following features of each specimen were assessed: aggregate length in 
millimeters, number of portal tracts, number of portal tracts with an interlobular bile duct, 
degree of fibrosis and Ludwig stage (4). The severity of fibrosis was expressed as a value 
ranging from 0-4 (15) and 0-5 for biopsies scored between 1990 and March 1994 and 
between March 1994 and 1998, respectively. The maximum score represents cirrhosis. The 
22 
amount of fibrosis was expressed as a fibrosis score, defined as a proportion of the 
maximum score. One biopsy per patient was included in the statistical analysis. 
The proportion of bile ducts was calculated by dividing the total number of portal 
tracts with an interlobular bile duct by the total number of portal tracts in each biopsy 
specimen. A ductopenic index was calculated by dividing the total number of portal tracts 
by the total number of portal tracts containing an interlobular bile duct. Thus, the higher 
the ductopenic index the more setious the loss of bile ducts. The degree of bile duct loss 
\vas also expressed as the biopsy length in millimeters divided by the number of bile ducts. 
For the index cases, the possibility of significant bile duct obstruction, which could 
possibly account for the discrepancy between the clinical features and the non-cirrhotic 
histology, was assessed by means of endoscopic retrograde cholangiography (ERe) andlor 
ultrasonography. Hyperthyroidism was evaluated by measurement of the Senll11 thyroid-
stimulating hormone (TSH) concentration. To exclude concomitant autoimmune hepatitis, 
the revised international score (16) was calculated. Hemolysis was assessed by serum 
lactate dehydrogenase (LD) and hematologic indices. Abdominal ultrasound with 
measurement of spleen size, upper gastrointestinal endoscopy for detection of 
esophagogastric varices and visual inspection of the liver duting laparoscopy or 
laparotomy were performed to further exclude the presence of cinhosis. Statistical analysis 
was performed with Stata 4.0 for Windows. COlTelations were calculated using Pearson's 
(1') or Spearman's (rs) tests. A p-Ievel <0.05 \vas considered statistically significant. 
Results 
Clinical, biochemical, histologic and radiologic characteristics of the four index 
patients are shown in Table I. All were females with a median age of 43 years (range 39-
47). Neither spontaneous nor therapy-induced improvements in hyperbilimbinemia or 
other laboratory parameters were observed. 
The mean age of the reference group (n:::::l0l) was 56 years (range 37-73); 87% were 
female and 95% were AMA-positive. Ludwig stages I, II and III were found in 20 (20%), 
51 (50%) and 30 (30%) biopsies, respectively. 
The median length of the 101 control biopsy specimens was 16 millimeter (range 4-40) 
and the median number of portal tracts per biopsy was 16 (range 4-44). The median 
number of portal tracts per millimeter liver tissue \vas 1.0 (95%-confidence interval 0.98-
U5). The number of portal tracts correlated well with the aggregate length of the biopsy 
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core (rs 0.7, p<O.OOI). The four cases did not deviate from the pattern among controls (fig 
I). 
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Figure 1. Scatter plot showing the relationship between biopsy length in millimeters and the number of 
portal tracts. Dots and stars (*) represent controls and cases, respectively. 
For our four cases, the proportion of portal tracts containing normal bile ducts was 3, 
4, 6 and 10 percent, yielding ductopcnic indice5 of 30, 28, 18 and 10, respectively. For the 
reference group, the median proportion of portal tracts with a bile duct was 45 percent 
(range 8.3 to 100%), a significant difference with the cases (Mann-Whitney test: p<O.OOI). 
The median ductopenic index for the reference group was 2.2 (range 1-12). 
The relationship between the degree of ductopenia and fibrosis is shown in figure 2. 
For the reference group, the ductopenic index was positively correlated with the degree of 
fibrosis (r=0.51 after logarithmic transformation of the ductopenic index to obtain normal 
distribution; p<O.OOl). This implies that only 26% (Le. r2) of the variability in fibrosis may 
be attributed to an association with the severity of ductopenia. Three out of four cases fall 
outside the 95%-reference interval (fig 2). Therefore, the degree of bile duct loss was 
significantly higher in our patients, especially when the slight amount of fibrosis is taken 
into account (fibrosis score 0.2 in three cases and 0.5 in one). When the number of bile 
ducts in related to the biopsy length, instead of the number of portal tracts, this ratio is 
significantly (1'<0.00 l) higher for our cases compared to the controls (fig 3). The extreme 
ductopenia is illustrated by a keratill-19 stained biopsy slide for one of the cases, shO\ving 
nearly total absence of pre-existent bile ducts (fig 4). 
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controls and cases. A high ratio indicates severe ductopenia. 
Other causes that might explain the apparent discrepancy between the severity of 
cholestasis and hyperbilirubinemia versus the minimal fibrosis in these PBe patients could 
not be identified. In particular, no evidence of hyperthyroidism, hemolysis, autoimmune 
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hepatitis (table I), previous use of agents known for their ability to induce cholestasis, or 
major bile duct obstruction was found. Laparoscopic examination of the liver, performed 
in three cases, showed normal livers without evidence of cirrhosis. In addition, 
ultrasonography (n=4) and upper gastrointestinal endoscopy (n;:::3) did not reveal signs of 
portal hypertension or evidence of other conditions, including cholelithiasis, liver 
metastases or lymphoma. Semm values for albumin and antithrombin-III \vere within 
normal ranges in all cases, retleeting an intact protein synthesis. 
Figure 4A. HE-coloured liver biopsy from case 2 showing at least 4 portal tracts. The amount of 
fibrosis is vcry limited and therc arc no porto-portal or porto-septal connections. 
Figure 4B. Anti-eytokeratin-19 (keratin-19)-stained liver biopsy from case 2 showing the same portal 
tracts as in figure 4A with total absence of pre-existent interlobular bile ducts and only very moderate 
ductular proliferation (darkish brown coloured cells). 
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Table I: Clinical characteristics of and diagnostic findings for our cases. 
Cme 1 2 3 4 
Age (yrs) 39 43 43 47 
Sex F F F F 
Ethnic background Chinese Caucasian Caucasian Caucasian 
Laboratory 
AMA positive positive positive negative 
ANA positive positive negative positive 
bilirubin (~molll; N<l7) 78 77 168 129 
APh (UlI: N<75) 709 926 761 848 
ALT (Un: N<50) 336 287 56 194 
IgM (gil; N<2.8) 4.07 4.13 4.52 9.19 
bile salts (~(molll; N<lO) 840 240 400 720 
cholesterol (mmoIn; N<6.5) 11.3 8.6 32.6 46.0 
TSH (mUll: N=0.20-4.20) 0.54 0.68 1.23 0.97 
LD (Un; N<480) 308 345 221 364 
Histology 
length ofhiopsy (mm) 21 28 18 25 
number of poriuliracis 28 18 10 30 
number of bile ducts J* 
Radiology 
ERe n.u. no stenoses no stenoses no stenoses 
abdominulultrasonography normal normal normal normal 
spleen size at US (em) n,a. 9-10 12 15 
visual liver assessment o.a, !lonnal normal nommi 
revised AlH score +8 +8 +2 +8 
upper GI endoscopy n.u. no p.b. no p.h. no p.h. 
Data obtaincd at the time oflivcr biopsy as indicatcd in the text. 
n.a.: not available; GI: gastrointestinal; p.h.: portal hypertension; US: ultrasonography; UDCA: 
ursodeoxycholic acid; "*: damagcd bile duct; ANA: antinuclear antibodics; APh: alkaline phosphatase; ALT: 
alanine aminotransferase. 
Discussion 
The cases described in the present report indicate that among patients with PBC a 
subgroup can be identified, characterized clinically by severe cholestasis and histologically 
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by extreme ductopenia which is not accompanied by significant liver fibrosis or ciIThosis. 
These patients do not seem to respond to treatment with ursodeoxychoIic acid or 
immunosuppressives and the disease evolves in the course of a few years to the stage in 
which liver transplantation becomes to be the only therapeutic option. The findings for this 
subgroup are at variance with the usual course of the disease whereby severe cholestasis 
and jaundice are only encountered in patients with cirrhotic histology. 
Jaundice in eady histologic stages of PBC has been observed before. Etiologies of this 
phenomenon, such as hemolysis (11, 12), hyperthyroidism (7) and concomitant 
autoimmune hepatitis (13), were not specifically related to PBC itself and ictems was 
reversible upon treatment of the underlying cause (7, 11, 13). No evidence for any of these 
possibilities was found in our cases. 
Histologic evaluation of the liver by means of needle-biopsy may be hampered by the 
possibility of sampling eITor. The accuracy of diagnosing cirrhosis, and consequently its 
absence, by percutaneous needle biopsy alone has been reported to be rather poor (17). 
However, a combination of this procedure ,,,ith ultrasonography enhances the sensitivity to 
nearly 100% (17, 18). Histology was combined with ultrasonography in our four cases. In 
addition, in three cases macroscopic assessment of the liver as well as upper 
gastrointestinal endoscopy was perfonned to further minimize the chances of missing a 
diagnosis of cirrhosis. 
Variability in the total size of the biopsy core influences the yield of portal tracts. The 
scatter plot (Fig 1) indicates that the biopsies obtained from our patients were comparable 
to those from the controls. The data show that approximately one portal tract per 
millimeter needle-biopsy tissue is found, confIrming the previously published I: 1 ratio 
(portal tract:millimeter needle biopsy) for the normal adult human liver (19). 
Consequently, since cirrhotic PBe was deliberately not included in this study, the 
ductopenic severity could also be expressed as the proportion of bile ducts per millimeter 
tissue. Presentation of the data in this way (fIg 3) demonstrates the extreme degree of bile 
duct loss in the jaundiced cases even more convincingly. 
Sampling error may also weaken the data on the severity of ductopenia. In this study 
little overlap in degree of ductopenia between the reference group and our cases was 
found. However, the difference in degree of bile duct loss between the case and control 
groups was statistically significant, both when the number of bile ducts was related to the 
number of portal tracts as well as to the length of the biopsy specimen. Furthermore, a 
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repeat biopsy in two of the cases (one 110n-cin-hotic liver explant) conftrmed the presence 
of striking ductopenia. 
This study does not allow other than speculations about the etio-pathophysiological 
differences behveen patients with the non-cirrhotic severe ductopellia variant and those 
with the more conventional course. \Ve found that the relationship bet\veen ductopenia and 
fibrosis, although present, is not velY convincing. \Ve hypothesize that in exceptional cases 
a particularly aggressive form of immune-mediated bile duct destruction results in 
extensive ductopenia within a comparatively short period of time. The relatively young age 
of our patients at presentation with severe cholestasis points to tIus possibility. Initially, 
ftbrogenesis seems to lag belund the rate of bile duct destruction_ Nevertheless, as 
indicated by the histologic evolution in our patients, progressive fibrosis eventually does 
develop. 
Previously, Nakanuma et a1. suggested extensive bile duct loss as a potential cause of 
cholestatic jaundice in non-cirrhotic PBC (20) without, however, rep0l1ing quantitative 
histologic data. The present study suggests that the proportion of portal tracts with an intact 
interlobular bile duct has to be less than 10% in order to produce substantial 
hyperbilimbinemia. Mild ductopenia, deflllcd as a proportion of portal tracts with an intact 
interlobular bile duct >50%, was shown not to be associated with a rise in serum bilirubin 
concentration in adults with 'idiopathic biliary dllctopenia' (21). Patent bile ducts in 10 to 
50% of portal tracts, as was found ill the large majority of patients in the refercnce group, 
was not associated with hyperbilirubinemia either. These percentages should not be 
regarded as absolute limits but rather as broad indications. Also, when assessing the degree 
of ductopenia the size of the biopsy specimen should always be taken into account. For a 
reliable assessment of ductopenia a nunimllm of 20 evaluable portal tracts has been 
suggested. (22). In clinical practice, howcver, tlus is not always feasible. 
Already in 1978, Popper hypothesized that in PBC two pathways may lead to cirrhosis 
(2). One is the consequence of biliary destruction within the portal triads and the other is 
due to peri-portal interface hepatitis that is mufonnly found in PBC, albeit to a variable 
extent. These two mechanisms may be opcrative in variable degree in individual patients. 
Consequently, one could speculate that PBe may have a wide range of phenotypical 
expressions, varying from a PBC-autoimll1une overlap syndrome on the one side to the 
'premature ductopenic variant' on the other side of the spectrum. Although it appears that 
both manifestations eventually may lead to cirrhosis, the name of the disease clearly needs 
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to be revised. 'Primary intrahepatic cholangitis' (PIC) (23) might be a more appropriate 
term. 
In conclusion, cholestatic jaundice in non-cinhotic PBC may be secondary to an 
unusually accelerated intrahepatic bile duct loss. Although the extent of fibrosis in affected 
patients may be limited initially, progression to cirrhosis seems to be inevitable. Despite 
intact protein synthesis and the absence of cinhotic complications, liver transplantation in 
the pre-cilThotic stage for treatment of pmritus and (prevention of) progressive weight loss 
due to malabsorption should be considered for these patients. 
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Appendix 
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K. Beering: Grocnc Hart Ziekenhuis Gouda; P. van Hecs: SI. Antonius Ziekenhuis, Nieuwcgcin; E. vd Hoek, 
J. de Bruijne: Carolus Ziekenhuis Den Bosch; iv1. Houben, R. Valentijn: Rode Kmis Ziekcnhuis Den Haag; 
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University Hospital 1'laastrieht; 1. Lambert: Sophia Zickcnhuis Zwolle; P. Leeuwerik: Ziekenhuis 
Lievensbcrg Bergen op Zoom; B. Looij: ~vlaasland Ziekenhuis Gelecn; A. Luckers: Maasziekenhuis 
Boxmeer; A. van Milligen dc Wit: Elisabeth Ziekenhuis Tilbllrg; C. van Nieuwkerk: University Hospital 
Frec University Amsterdam; J. den Ouden-Muller, A. van Tilburg: St. Francisclls Gasthuis Rottcrdam; S. 
Peters, P. Tjepkema: I1ssclmeer.liekenhuizen Lelystad; G. Ras: Ignatius Zickenhuis Breda; lvL Rijk: 
Ziekenhuis Dc Baroruc Breda; R. Robijn: Ziekenhuiscentrum Apeldoom; S. Schalm: University Hospital 
Rotterdam; 1. Scherpenisse: Reinier dc Graaf Gasthuis Delft; A. Stronkhorst: Catharina Ziekenhuis 
Eindhovcn; T. Tan: Strcckziekenhuis Midden-Twenle Hengclo; 1. Thijs: Ziekenhuis Bethesda Hoogcveen; 
K. te Veldc: Dcvcnter Ziekenhuizen Dcventer; M. Vidakovic-Vukic: Lucas Andreas Zieken1mis Amsterdam; 
A. van Vliet, R. Beukers, H. Ponsscn: Albert Schweitzer Ziekenhuis Dordrecht; R. dc Vries, C. Mulder, J. 
Thies: Ziekenhuis Rijnstate Arnhem; S. vd Wcrf: Wcsteinde Ziekenhuis Den Haag; B. Witteman, J. van 
Bergeijk: Ziekenhuis De Geldersc Vallei Wageningen; R. van Zanten: Twenteborg Ziekenhuis Almelo; R. 
Zcijen: Schieland Ziekcnhuis Schiedam; R. Zwertbrock: Westfries Gaslhuis Hoom; A. Saleh: Elisabeth 
Hospitaal Willemstad, Curacoa. 
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Abstract 
Traditionally, autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) 
are regarded as separate disease entities. \Ve report on a group of patients that suggests the 
existence of an overlap syndrome of the two conditions and on the prevalence of this 
syndrome among patients \vith PSC. Furthermore, the impact of the recently revised AIH 
scoring system for diagnosing AIH in this context was assessed. Retrospective analysis of 
consecutive patients of a tertiary rcfenal centre for liver disease with a diagnosis of PSC. 
Diagnosis of the overlap syndrome was established for nine patients (8%) of a total group 
of 113 PSC patients. Four patients initially presented with features of AIH and in five 
cases PSC was diagnosed rust. All patients responded to immunosuppressive therapy, in 
three cases long-term remission was achieved. Three patients underwent liver 
transplantation after 4 months and 7 and 9 years. The original and revised versions of the 
AIH scoring system gave essentially the same results in the patients with the PSC-Am 
overlap syndrome. Patients with overlapping features of Am and PSC may be more 
common than is currently assumed. Recognition of this syndrome is of clinical significance 
considering the important therapeutical consequences. 
Introduction 
Autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC) nnd primary biliary 
cilThosis (PBC) are usually regarded ns separate disease entities. On the basis of clinical, 
biochemical, sera-immunological, histological aud radiological criteria, a clear distinction 
between these conditions can readily be made in the majority of cnses. However, Am, 
PSC and PBC also have many features in common. In particular, autoimmune-mediated 
necro-infianunatory damage of hepatocytes and bile ducts seems to be of primary 
pathogenetic importance (1-5), 
111 other autoimmune diseases the occurrence of patients with overlap syndromes hns 
been clearly established (6). In recent years, syndromes ,,,Hh overlapping features of Am 
and PBC have also been recognised increasingly (7-11). Furthermore, the simultaneous 
presence of AIH and PSC has been described, especially in children (12, 13) but also in a 
number of adults (14-20), Recent review articles, however, (4, 5, 21, 22) do not refer to 
this syndrome, illustrating that it is still believed to be rare. Our senior authors (HRvB and 
SWS) have noticed over a 20-year period a change in the phenomenology. of AIH, in 
particular an increase in incidence in young llnles, often with cholestatic features and 
regular occurrence together with PSC. To verify tIus clinical impression, a retrospective 
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study was initiated. We report here our single~centre experience with nine patients with an 
AlI-I and PSC overlap syndrome. 
Patients amI Methods 
An exhaustive survey was performed to identify all consecutive cases with a diagnosis 
of PSC in our centre since 1976. The diagnosis was based on cholangiography showing 
(multi)focal strictures of intrahepatic and/or extrahepatic bile ducts with intervening 
normal or dilated segments, producing a beaded bile duct appearance. Originally, 
cholangiograms were studied by a senior radiologist with a special interest in endoscopic 
retrograde cholangiography (ERC); for the purpose of this study all cholangiograms were 
reviewed by the first author. PSC was not diagnosed if bile duct abnormalities could 
possibly be attributed to such causes as previous bile~duct surgery, ischaemia, portal vein 
thrombosis or sclerosing pancreato-cholangitis (23). 
The clinical diagnosis of AIH was based on the finding of at least three~fold elevations 
in serum transaminase activities, elevated concentrations of IgO or y-gJobulills and 
positive tests for antinuclear antibodies (ANA), smooth muscle antibodies (SMA), 
perinuclear antineutrophile cytoplasmic antibodies (pANCA) or Iiver~kidney microsomal 
antibodies in combination with liver histology showing moderate or severe chronic active 
hepatitis with interface hepatitis and a predominantly lymphoplasmacytic infIltrate. 
Patients were assumed not to have AIH if there wns evidence for viral hepatitis or some 
other concomitant liver disease, except for PSC, and if anti mitochondrial antibodies 
(AMA) were present. Immunofluorescence techniques were used to detect autonntibodies. 
pANCA was detected all granulocytes, ANA 011 Hep2 cells, AMA on mouse and rat 
kidney cells and SMA on rat stomach cells. 
In order to verify our clinical diagnosis of AIH, the numerical scoring systems for the 
diagnosis AIH, proposed by an international group of experts during a consensus meeting 
in 1993 (24) and modified by the same group in 1999 (25), were applied to all patients, In 
nccordance with others who applied this diagnostic system to patients with PSC (26) scores 
were obtained before therapy. 
Data relevant for this study were extracted from patient files and data~banks of the 
radiological, pathological, biochemical and inmll111010gical departments. All pntients were 
followed until December 1998 or until death. 
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Results 
In the period 1976-1998 113 patients with PSC were identified in our center. Nine 
patients (8%) fulfilled the diagnostic criteria for both AIR and PSC (table I). The age at 
presentation of these nine cases with either one of these conditions varied from 7 to 54 
(mean 27) years. An overlap syndrome was diagnosed after intervals varying from 6 
months to ll.s (mean 5.8) years. The duration of foHow-up ranged from 1 to 16.8 years. 
Eight patients had concomitant IBD; in the one remaining case colonas-copy was not 
pClfornled. 
Four patients (no 1-4),2 males and 2 females, mean age 16 (range 7-22) years, were 
initially diagnosed with AIH (table 1). In all cases the serum transaminase levels were 
elevated at least ten-fold (mean 18 times the upper limit of normal), IgG or y-globulin 
concentrations were raised, SMA andlor ANA were detected and the Jiver biopsy showed 
interface hepatitis with a Jymphoplasmacytic infiltrate (figure 1). Marked biochemical 
improvement was observed after treatment with prednisone and azathioprine (table 2). 
Mainly because a predominantly cholestatic biochemical prof.tle emerged during follow-
up, ERe was perfonned at intervals after the initial diagnosis, varying from 5.9 to 11.5 
(mean 8.9) years. Despite an initially favourable therapeutic response to 
immunosuppressive therapy, patient no 4 had slowly progressive disease necessitating liver 
transplantation after 7 years. The remaining three patients are alive and are still being 
followed; long-term complete biochemical remission was achieved in one patient with 
continued immunosuppressive treatment. 
Figure I. Liver biopsy showing an enlarged portal mea with a predominantly lymphopJasmacytic 
inftltrate with an ill-deftned limiting plate and (top) inflammatory cells inft.ltraling into the adjacent 
parenchyma (patient no I). Original magnification x 20. 
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Five patients (no 5-9), four men and one female with a mean age of 32.6 (range 15-54) 
years, were initially diagnosed with PSC (table l). Liver histology showed 
periocholangioiar fibrosis in two cases; pANCA was detected in three cases and four 
suffered from concomitant IBD. AIH was diagnosed after a mean interval of 3.3 (range 
0.5-5.8) years. One of these patients (no 5) exhibited the classical features of AIR: 
transaminases elevated ten-fold, IgG 49 gil, high Htres of SMA and histologically severe 
chronic active hepatitis. PSC had been diagnosed elsewhere six years earlier; in the course 
of time he exhibited persistently elevated transaminases and had an episode of severe 
hepatitis which resolved spontaneously. In retrospect, the diagnosis of AIH could have 
been established six years earlier. Another patient (no 6) developed liver failure ,vith 
variceal bleeding and ascites when corticosteroids were withdrawll following colectomy 
for ulcerative colitis. Renewed immunosuppressive treatment resulted in complete clinical 
and long-term biochemical remission. Another patient (no 7) developed AIR when the 
corticosteroids, ,,,hich he had received for 8 weeks in the context of a controlled clinical 
trial for PSC, were tapered off. These three patients (no 5-7) are alive and arc being 
followed. The fourth patient (no 8) remained jaundiced after hepaticojejullostomy for 
common bile duct strictures. During immunosuppressive treatment bilirubin, 
transaminases, APh and immunoglobulins normalised or decreased significantly (table 2). 
Nine years later, hmvever, he received a liver transplant for progressive disease. The last 
patient (no 9) was known with PSC for one-and-half years when severe jaundice and 
hepatic insufficiency developed. The initial diagnostic and therapeutic efforts focllssed on 
the bilialY tree. Only after five months immunosuppressive treatment was instituted. Four 
months later liver transplantation was performed because of insufficient therapeutic 
response. 
Six patients, five ,,,ith an initial diagnosis of PSC, received UDCA during the course of 
their disease at various intervals after the date of diagnosis. This treatment appeared to 
result in slight improvements in the serum liver tests in some cases. 
ERe revealed bile duct changes characteristic of PSC in all cases. Mild abnormalities of 
both intrahepatic and extrahepatic ducts were found in 3 patients while only the 
intrahepatic ducts were affected in 2 patients. In 2 patients marked intrahepatic bile duct 
deformities were found, one was associated with intrahepatic stones wllile the extrahepatic 
ducts appeared to be normal. Dominant strictures were observed in one patient (no 8). 
Severe intrahepatic and extrahepatic PSC was found in patient 9 (figure 2). 
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Figure 2. Endoscopic retrograde cholangiogram (patient no 9) showing multiple areas of intrahepatic 
strictures and ductal dilatation. 
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Figure 3. Distribution of the numerical AnI-scores of both the 1993 and 1999 scoring lists in the tolal 
group of 113 PSC patients. The black and while bars represent the results according to the 1993 and 
1999 lists, respectively. 
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Comparison of the outcomes of the original and revised AIH scoring systems gave 
essentially the same results for the cases with a clinical diagnosis of both AIR and PSC 
(table 1). Both the original and revised version of thc scoring list resulted in scores 
indicating 'definite' AIH in eight cases and 'probable' AIH in one. In the total group of 
113 PSC patients, the 1999 scoring list gave lower numerical AIH-scores than the 1993 list 
(figure 3). 
Discussion 
In this report nine patients with an overlap syndromc of AIR and PSC are described. In 
view of the number of cases reported in the literature (table 3) this represents a relatively 
large series. It is noteworthy that four more patients have been identified with AIH who 
had marked cholestatic liver function test abnormalities, negative test results for AMA, and 
histologically chronic active hepatitis with dnchllar changes, pericholangiolar fibrosis and 
copper deposits. A definite diagnosis of PSC, however, could not be made because 
cholangiography was not performed. 
Specific referral pattellls and incrensed diagnostic aWareness in recent years may have 
contributed to the number of cases reported here. The prevalence of the overlap syndrome 
among patients with AIH remains to be established because none of the studies reported, 
including the present one, included cholangiography in all cases. Among children with 
Am a prevalence of 27% was reported, but also in this study cholangiography was not 
performed uniformly (27). The prevalence of AlH among patients with PSC was assessed 
by Boberg et al. (26), who applied the 1993 AIH scoring system to a group of 114 PSC 
patients. Two (2%) patients were classified as 'definite' Am and 38 (33%) as 'probable' 
AnI. We found a prevalence of 'definite' AIH of 8% in our group of 113 PSC patients. 
Establishment of the diagnosis of Am is difficult since there is no single diagnostic 
test or validated sct of critclia. This applies specifically for patients with a concomitant 
liver disease. The diagnostic aspects of AlH were addressed by an international [olUm of 
experts during consensus meetings in 1993 (24) and 1999 (25). In our centre we rely 
mostly on the positive criteria of >3-10 fold elevations of serum transaminases, two-fold 
elevation of IgG or gal11l1lagiobulins, presence of auto-antibodies and compatible liver 
histology. Negative factors such as alcohol use, positive viral serology, hepatotoxic 
medication and biliary lesions on biopsy are clearly considered, but we do not attribute a 
decisive significance to these factors. The reports of the 1993 and 1999 meeting (24, 25) 
stales that patients with biliary changes identitled either histologically or by 
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cholangiography should not be assumed to have AIH. This point of view should be 
modified in the light of cumulating evidence that true overlap syndromes do occur (28). 
\Vith these reservations in mind, our patients were evaluated according to the 1993 and 
1999 systems. The scoring systems were applied conservatively and resulted in scores 
indicating 'definite' Am for eight patients and 'probable' AIH for one. The latter patient, 
however, exhibited a complete biochemical response to immunosuppressive therapy. The 
observed response to immunosuppressive therapy in the other cases further strengthens our 
belief that all of our patients had AIH. Essentially, application of the recently revised Am 
numerical scoring system for diagnosing AIH did not atlect the results obtained with the 
1993 version. Therefore, both systems seem appropriate tools for identifying PSC patients 
,vith concomitant AIH. Although we applied both scoring lists to all 113 patients for 
methodological reasons, we do not feel that this is rational approach in daily practice. In 
our opinion, application of the scoring list should only be considered in case of clinical 
evidence of concomitant AIH. 
When the clinical features of patients in the present series are compared with those of 
previously rep0l1ed adult patients (table 3) with AIH-PSC overlap, several similarities are 
found: percentage males is 67% versus 66% in the literature, mean age at presentation 27 
versus 26 years and prevalence of IBD 89% versus 59%, respectively. \Vith respect to 
other laboratOlY, histological and radiological characteristics, these patients seem to be 
very similar. The presently available cumulative experience indicates that the Am-PSC 
overlap syndrome is mainly, but not exclusively, a disorder encountered in children and 
young adults, with a predominance of males. In the majority of cases the overlap syndrome 
is associated with ulcerative colitis or Crohn's disease. 
The therapeutic response to immunosuppressants, in particular of the AII-I-component 
of the overlap syndrome, can be excellent. Our experience as well as that of others (15, 16, 
18) indicates that proper therapy can lead to complete remission of disease activity and 
indeed may be life-saving. However, our experience seems to be in accordance with that of 
earlier reports (12, 14,29,30) suggesting that the therapeutic benefit for patients with an 
overlap syndrome may be less than for those with 'genuine' AIH. In fact, two of our 
patients needed a liver transplant 7-9 years after the start of immunosuppressive therapy. 
This finding is in contrast to cun-ent results for genuine AIH (31). One may speculate that 
the immunosuppressive treatment does not influence the PSC-component of this overlap 
syndrome in a major way. In the patient who was transplanted after four months, 
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immunosuppressive therapy probably was instituted at a stage of irreversible hepatic 
damage. 
The cause of AIH and PSC is unknown. Most findings seem to indicate that these 
disorders may develop in patients with a genetic susceptibility. Human leucocyte antigen 
(HLA) studies have shown that both disorders are closely associated with B8, DR3-
positive haplotypes (26, 32) and with the DRB3 allele DRB3*0101, which encodes for 
DR52a (33, 34). The results of detailed HLA typing have not been reported for patients 
with the overlap syndrome and tIus therefore requires further study. The many similarities 
between the clinical, histological, genetic and immunological features of AIH and PSC 
(26, 35) and the existence of an overlap syndrome may suggest that these conditions 
represent phenotypic expressions of a common underlying process with aberrant 
autoreactivity. The role of IBD \vithin tIus concept is even more speculative. IBD is 
associated with both PSC (4, 5, 36) and Am (29) and the majority of overlap patients had 
IBD. In theory, IBD could be another phenotypic manifestation of a common underlying 
disease process. On the other hand IBD could be a condition that facilitates the 
development of AIR and PSc. 
In conclusion, we report on nine patients with an overlap syndrome of AIH and PSC, 
which brings the total number of reported cases to 38. Our experience suggests that this 
entity may be less rare than cun'ently assumed. Clilucians should be well aware of this 
syndrome since recognition of these cases can have major therapeutic implications. 
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Table 1: Patient characteristics at presentation and laboratory findings at the time of diagnosis of AIR. 
Patient sex age lED initial Diagnostic original Revised histology IgG y~glob SMA ANA pANCA 
diagnosis interval AlB AlB (gil) (g~) 
AlB-PSC score score 
(yrs) 
M 7 UC AlB 11 16 16 iib, h 29.4 1:10 >1:640 
2 M 14 UD AlH 11.5 17 16 iib. f 49.2 1:40 1:80 
3 F 21 UC AlB 5.9 19 20 iib. f 40 neg 1:2560* 1:160 
4 F 22 CD AlB 7.3 19 19 ifh 34 1:320* 1:80* 
5 M 20 UC PSC 5.6 18 17 pcf. lib 49.4 1:320 neg neg 
6 M 0' _0 UC PSC 2.9 16 16 itb. c 34.8 neg 1:180 1:10240* 
7 M 37 no PSC 5.8 15 13 ifh. f 23.2 neg 1:2560 neg 
8 M 54 UD PSC 0.5 17 17 iib. f 53.1 1:80 1:40 
9 F 44 UC PSC 15 17 19 pef. ifh. f 32.6 neg neg 1:160 
mD: inflammatory bowel disease: UC: ulcerative colitis: CD Crohn's disease: UD undetermined colitis 
AIR score: score according to international autoimmune hepatitis group before immunosuppressive treatment (24), A score >15 indicates definite AIR and a score of 
10 to 15 probable AIH. 
iib: interlace hepatitis, pef: pericholangiolar fibrosis. f:fibrosis. c:cirrhosis .• data 3-4 years after diagnosis AIR 
Table 2: Serum liver tests and IgG/y-globulins during the first year of immunosuppressive treatment. 
bilirubin Q.unolJI) AST (Un) 
patient start 1 1 year Start 1 1 year start 
month month 
1 52 10 9 364 38 72 458 
2 22 19 18 470 30 172 338 
3 123 n.a. 10 918 149 12 35 
4 46 11 15 348 82 97 135 
5 459 148 29 410 81 45 166 
6 307 450 36 750 332 112 87 
7 54 27 II 303 23 14 117 
8 117 20 9 432 99 106 119 
9 467 496 LTx 538 343 LTx 218 
reference values: APh <75 U/l: AST <30 VII: bilirubin <17 )lmol/l: IgG <16 gil: y-globulins 9-18 gil 
>I< y-globulins: LTx: liver tr.lnsplantation: n.a.: not available 
APh (Un) IgG/y-globulin (gil) 
1 1 year start 1 1 year 
month month 
146 397 29.4 n.a. n.a. 
223 458 49.2* n.a. n.a. 
33 17 40* n.a. 18' 
80 97 34* n.a. n.a. 
151 95 49.4 36 13.9 
100 122 34.8 19 21 
55 120 23.2 12.8 9.9 
90 82 53.1 21.6 28.4 
210 LTx 32.6 18.9 LTx 
Table 3: Case series of the PSC-AIH overlap syndrome. 
Author Year n IBD Treatment Therapeutic response 
Minuk (14) 1988 2 UC Prednisone Poor 
Rabinovitz (15) 1992 UC Prednisone/azathioprine Good 
Perdigoto (29) 1992 5 UC Prednisone/azathioprine treatment failure (n=4) 
transplantation (n=2) 
Lawrence (16) 1994 UC Cyc1osporine good 
Wurbs (17) 1995 1 No Prednisolone/azathioprine good 
Gohlke (18) 1996 3 UC (n=l) Prednisoloneia:zathioprinelUDCA remission (n;;;;1) 
Boberg (26) 1996 2 UC Corticosteroids (n=1) death (n=l) 
transplantation (n=l) 
Protzer (19) 1996 4 UC (n=l) Corticosteroids/azathioprine good 
Luketic (30) 1997 5 UC (n=2) Corticosteroids/azathioprine Liver transplantation (n=4) 
McNair (20) 1998 5 UC (n=2) Prednisolone/azathioprine good biochemical response 
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Abstract 
Ten male patients are described who presented with weight loss, jaundice and prutitus. 
Pancreatic cancer was suggested by imaging studies showing focal or generalized 
pancreatic enlargement and compression of the distal common bile duct. In one case 
pancreatoduodenectomy was pctformed. Cholangiography, however, also demonstrated 
intrahepatic biJimy stenoses, consistent with sclerosing cholangitis. Exocrine pancreatic 
insufficiency was found in six patients and diabetes in four. Pancreatic histology showed 
l1brosis and extensive inflammatory infiltrates. No evidence of concomitant IBD was 
found. A clear response to immunosuppressive treatment was observed in several patients. 
Notably, clinical and biochemical remission was observed in 3 patients and in one patient 
previously documented intrahepatic biliary strictures had disappeared after 3 months. The 
clinical features, pancreatic involvement, relatively high age at presentation, absence of 
IBD and response to steroids all plead against a diagnosis of 'ordinary' PSC. The natural 
course of sclerosing pancreato-cholangitis that may be accompanied by other disorders 
including Sjogren's disease is highly variable. Since the disease may mimick pancreatic 
carcinoma and, unlike PSC, may respond to immunosuppressives, recognition of cases is 
of clinical importance. 
Introduction 
Intrahepatic and extrahepatic bile duct strictures may result from a broad array of 
causes, such as biliary ischemia (I), AIDS (2), arterial administration of cytotoxic agents 
(3), portal vein thrombosis (4) and primmy sclerosing cholangitis (PSC) (5). PSC is a 
disease of unknown etiology, with many findings suggesting an (auto)iml11une 
pathogenesis. The majority of patients has concun"ent inflammatory bowel disease (lBD) 
(5). Pancreatic involvement in PSC is considered to be rare (6, 7). 
Recently, autoimmunity was proposed as potential cause of a distinct type of 
idiopathic chronic pancreatitis (8-14). Clinical findings at presentation, in combination 
with radiological imaging studies showing pancreatic enlargement, led to a high initial 
sllspicion of pancreatic cancer in the majority of reported patients. This type of pancreatitis 
can be found in the absence (8-12) or presence of other putative autoimmune diseases, 
such as Sjogren's disease (14-16) and systemic lupus erythematosus (17) and IBD (13, 18-
21). 
We here report on ten patients \VI1O presented with clinical signs suggestive of 
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pancreatic carcinoma but were found to suffer from idiopathic chronic pancreatitis in 
association with a PSC-Uke bile duct disease. From ollr experience we believe that these 
patients did not merely have atypical PSC with coincidental pancreatic involvement, but 
rather had a distinct autoimmune-mediated disease involving the pancreato-biliary tract. 
This entity may be less rare than is suggested by sporadic literature reports of comparable 
cases (13, 22-42). Recognition is of major clinical importance, in particular since the 
disease may mimick pancreatic cancer and, unlike PSC, may respond to conventional 
immunosuppressive therapy. 
Patients and methods 
In the period 1992-1999 ten patients with both pancreatic disease, in all clinically 
mimicking pancreatic carcinoma, and a concurrent or subsequent diagnosis of multiple 
biliary strictures were identified. Patients were followed until January 2000. Data were 
obtained from patient charts. All relevant radiological studies and histology specimen were 
reviewed for the purpose of the study. 
Explorative laparotomy. abdominal computed tomography (CT) and/or 
ultrasonography (US) were used to assess pancreatic anatomy. Pancreatic tissue specimens 
were obtained by needle biopsy or pancreatoduodenectomy. Endocrine and exocrine 
pancreatic functions were evaluated by means of measurement of semm glucose level and 
fecal pancreatic elastase-I content (ScheBo-Tech GmbH, \Vettenberg, Germany), 
respectively. 
Bile duct anatomy was assessed ,,,ith endoscopic retrograde cholangiopancreatography 
(ERCP) or percutaneous transhepatic cholangiography (PTC). Liver histology specimen 
were obtained by needle biopsy. Colonoscopy was performed to diagnose IBD. 
Immunofluorescence techniques were used to detect perinuclear antineutrophH 
cytoplasmic antibodies (pANCA). 
Case .. epo .. ts 
Case A (patiellt 110. I) 
This 63-year old male patient presented with a history of 6 kg weight loss over 3 
months. He had frequent pale, sticky stools and dark mine. His previous medical Wstory 
was unremarkable. Laboratory examination revealed hyperglycemia (19.1 mmollJ, normal 
<5.5), cholestasis (APh 539 VII, nonnal <130; )<iT 635 uti, norlllal <50; bilirubin 12 
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funol/I), slightly elevated transaminase levels (AST 49 UI!, normal <40; ALT 69 UI!, 
normal <45) and elevated CA19.9 (330 kUI!). Carcinoma of the pancreas was suspected. 
US and CT studies (Fig I) showed a diffusely enlarged "sausage"-like pancreas and a 
thickened aspect of the common bile duct wall. ERCP demonstrated multiple intrahepatic 
bile duct strictures, consistent with sclerosing cholangitis, and a narrowed pancreatic duct 
without strictures. Liver biopsy showed periductal inflammation. COIOIlOSCOPY was 
normal. Treatment with prednisone (60 mg/day), ursodeoxycholic acid (UDCA) and 
pancreatic enzyme substitution was instituted. Complete normalization of serum liver 
biochemistry (APh, AST and ALT) and CA19.9 level was observed within three months. 
Bodyweight increased by 10 kg over a period of six months. After tapering off the 
prednisone and introduction of azathioprine (2 mg/kg bodyweight), glucose serum levels 
,,,ere within normal limits with dietary measures. Exocrine pancreatic insufficiency, which 
was not assessed at presentation, appeared to be present after prednisone therapy. During 
the subsequent two years of follow-up he remained in excellent and stable clinical 
condition. Repeat ERCP after two years showed diminution of biliary strictures. 
Figure 1. Computed tomography scan of patient no I showing enlargement of the pancreatic head 
region. A biliary endoprosthesis is located in the centre. 
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Case B (patiellf no. 3) 
TIlis 48~year old male patient was admitted with complaints of pmritus, abdominal pain 
and 30 kg weight loss. In the past, he had received a comcal graft for keratoconus. Diabetes 
mellitus was diagnosed and treated with oral medication. One month later painless jaundice 
developed (bilimbin 126 J.Imolll, llOlll1ak17; APh 212 UII, normal <130; ')CiT 1423 UII, 
normal <70; AST 270 UII, nonnal <45; ALT 680 UII, normal <50). ERCP demollstrated 
marked stenosis of the distal common bile duct. Carcinoma of the pancreatic head or distal bile 
duct ,vas suspected and a biliary stenl was placed. DUling subsequent explorative laparotomy 
multiple petitoneal spots, enlarged omental lymph nodes and an enlarged pancreas with a 
rough surface were found. Microscopy of snap-frozen tissue samples suggested 
adenocarcinoma. Consequently, the plan to perfonn a Whipple's resection was abandoned. 
Definitive histological examination, however, failed to confum a diagnosis of malignancy. 
TIle patient did not consent to a proposed pancreatoduodcncctomy and asked for a second 
opinion clsewhere. Repeated ERCP revealed multiple intra- and extrahepatic bile duct 
strictures with focal nm1"owing of the distal common bile duct (Fig 2); the pancreatic duct was 
nalTOW and il1'egulm'. Liver biopsy demonstrated portal inflammatOl)' infiltrates and moderate 
lobular fibrosis. Co!onoscopy with biopsies was normal and serum pANCA negative. Fecal 
elastase-l content «0.015 mg/g) indicated severe exocrine pancreatic insufficiency. Liver 
biochemislly nonnalized spontaneously; pancreatic enzyme suppletioll was instituted and a 30 
kg weight gain over a period of one and a half year was observed. Subsequently, renal failure 
and generalized lymphadenopathy developed, accompanied by complaints of migrating 
polym1hralgia, fhtigue and dl)'ness of eyes and mouth. Sjogren's disease was diagnosed based 
on clinical findings, abnonnal Schinner test results and renal and lip biopsies showing 
interstitial nephritis and salivaJ)' adenitis, 
Results 
We observed ten patients (Table I) with PSC-Jike bile duct abnormalities on ERCP (n~9) 
or PTC (n=l) in combination with an enlarged, malfullctioning pancreas in the period 1992-
1999. All patients were males and the age at presentation varied from 19 to 80 (mean 55) 
years. Weight loss (n~ 10), jaundice (ll~8) and pmritus (n~ 7) were the main presenting 
symptoms. One patient had a histOl)' of alcohol abuse. None of the patients had clinical 
evidence of concunent IBD; colonoscopy was performed in six patients with normal findings. 
Serum pANCA was negative in all seven cases tested. 
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Figure 2. Endoscopic retrogrttde cholangiography in patient no 3 demonstrating multiple inlmhcpatic 
and extrahepatic biliary strictures and focal narrowing of the distal common bile ducl. 
Pancreas 
At presentation, carcinoma of the pancreas was suspected in all patients. CT was 
performed in 9 patients and demonstrated diffuse pancreatic s\velling (n=3) or focal tumor-
like (n=3) or diffuse (n=3) enlargement of the pancreatic head region. On US diffuse, 
sonolucent swelling was found in four cases and a mass confined to the head region in six. 
Pancreatography, performed in six patients, revealed a naITOW, irregular pancreatic duct 
(11=3) (Fig 3), an irregular duct with focal narrowing, dilatations and ductectasia of side 
branches (n=2) or a pre-papillary tight stenosis (n=l). Severe exocline pancreatic 
insufficiency (fecal elastase-l content <0.015 mg/g) was found in six of seven patients 
tested and endocrine insufficiency in four out of ten. 
During laparotomy, performed in five patients (no. 3, 7-10), the pancreas proved to be 
markedly enlarged and finn; on palpation notable firmness of the common bile duct was 
also noted. Pancreatic tissue was obtained by per-operative needle biopsy (no. 8 and 9) and 
pancreatoduodenectomy (no. 7). Histological evaluation demonstrated chronic fibrosing 
pancreatitis with lymphoplasmacellular and eosinophilic infiltrates (Fig 4) and fibrosing 
inflammation of the common bile duct. Malignancy was not found. 
Choledochoduodenostomy was pelformed in one patient (no. 10). 
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Figure 3. Endoscopic retrograde pancreatography of patient no 3 showing a narrmv, irregular 
pancreatic ducl. 
Figure 4. Pancreatic histology of patient no 7 demonstrating fibrosing pancreatitis with eosinophilic 
and Iymphoplasmacellular infiltrate. 
52 
Bilill1)' tree alld liver 
Laboratory examination shmved cholestasis in all patients, with hyperbilimbinaemia in 
8 (Table I). Cholangiography revealed intrahepatic and extrahepatic bile duct strictures and 
suggested an enlarged pancreatic head in all cases. Liver histology, available for eight 
patients, was consistent with chronic cholestasis (Table I). Portal infiltrates were mainly of 
lymphopiasmacellular and eosinophilic origin. The degree of interface hepatitis varied 
from absent to slight and the amount of fibrosis from absent to marked. Per1cholangioiar 
"onion-skin" fibrosis was not observed. 
Treatmellf and COllrse of disease 
Seven jaundiced patients (no. 2, 3, 4, 6, 7, 9, 10) received temporary biliary stent 
therapy for stenosis of the distal common bile duct, resulting in decreases of serum 
bilirubin level and other liver test parameters. 
Five patients were treated with immullosuppresives (no. 1,2,6,8,10). Four (no. 1,2, 
6, 8) received prednisone (30-60 mg/day) tapered to maintenance doses (5-10 mg/day) 
within 2 months; two patients (no. I and 2) also took UDCA and one (no. 6) received 
concomitant azathioprine 50 mg/day. Complete biochemical remission ensued in all four 
cases within six months. In one patient (no. 6) the centrally located intrahepatic bile duct 
strictures and the common bile duct narrowing in the pancreatic head region had 
disappeared after three months of prednisone, azathioprine and biliary stent therapy. In the 
01 her 3 cases (no 1, 2, 8) follow-up cholangiography after two years showed marked 
improvements. Prednisone treatment was withdrawn after approximately one year in 
patients 1, 2 and 6. In these cases semm biochemistry remained normal during follow-up. 
In patient 8, prednisone was also withdrawn after one year. After three months serum 
levels of APh, )'GT, AST and ALT increased again and prednisone therapy was 
reintroduced, followed by rapid biochemical normalization. In patient J 0, prednisone (10 
mg/day), azathioprine (50 mg/day) and pancreatic enzyme treatment were started six years 
after presentation. At that time liver histology showed cirrhosis. During the 2 month 
follow-up period serum bilirubin level decreased from 60 to 53 Jl11l01/1 and serum albumin 
levels rose from 32 gil to 37 gil. 
One patient (no. 1) with manifest diabetes. mellihls became nonnoglycemic during 
corticosteroid therapy. Patients 2 and 6 developed transient diabetes mellitus during 
corticosteroid treatment. In patient 6, pre~treatl11ent fecal elastase-l content of <0.0 15 mg/g 
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increased to normal values of 0.089 mg/g, 0.159 mg/g and 0.249 mg/g after three, five and 
twelve months, respectively, of combined prednisone-azathioprine treatment. 
Pancreatography was not repeated. 
UDCA (600 mg/day) treatment in patient 4 did not result in sustained improvement in 
serum liver biochemistry, whereas in another (no. 5), marked improvements, although no 
normalization, in serum liver function tests was found after starting treatment with UDCA 
(750 mg/day). In this patient, a second ERCP performed after tlVO years of UDCA therapy, 
showed largely the same abnormalities. Patient 10 remained jaundiced despite treatment 
with UDCA (750 mg/day). In contrast, complete biochemical remission without any 
medical intervention was observed in patients 3 and 9. 
In case 7, initial ERCP shmved a stenosis of the common bile duct in the pancreatic 
region; no adequate images of the intrahepatic bile ducts were obtained. CT and 
laparoscopic intra-abdominal US showed a tumorous pancreatic mass and multiple 
enlarged regional lymph nodes. Pancreatoduodenectomy was performed. Histological 
examination demonstrated a chronic fibrosing inflammatory process involving the 
pancreas and common bile duct and non-specific, reactive lymph node abnormalities. 
Postoperatively, serum bilirubin levels normalized completely. Six weeks after the 
operation, however, he was readmitted because of recurrent jaundice (bilimbin 304 
1111101/1). ERep now showed numerous intrahepatic bile duct strictures (Fig 5). US and 
angiography of the hepatic artery. performed to rule out ischemic damage to the biliary 
tree, were normal. No specific treatment was instituted. Serum bilirubin levels normalized 
spontaneously while APh and "j'G-T remained moderately elevated. Again, hvo years later 
symptoms of weight loss and pruritus recurred, accompanied by marked icteric cholestasis 
(bilirubin 120 ~lmoll1) and notable hypergammaglobulinaemia (seruln [gO 31.7 gil, normal 
<15.5). 
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Figure 5. Endoscopic retrograde cholangiography 6 weeks after pancreatoduodenectomy was 
perfonned in patient no 7, showing severe multiple bile duct strictures and dilatations. 
Discussion 
In this report ten patients with an intriguing inflammatOlY disorder of the pancreato-
biliary tract are described. A number of comparable cases has been reported during the last 
25 years (Table II). Usually these patients were considered to have PSC with coincidental 
idiopathic chronic pancreatitis. "Many descriptive names have been used, including 
'lymphoplasmacytic sclerosing pancreatitis with cholangitis' (34), 'pancreatic 
pseudotumor with idiopathic fibrosclerosis' (29), 'inflammatory pseudotumor from 
sclerosing cholangitis' (25) and 'primary sclerosing cholangitis mimicking chronic 
pancreatitis' (30). Since we became aware of tIus particular syndrome we recognized 
several additional cases, particularly among patients previously regarded as having an 
atypical form of PSC or an ill-defined cholestatic-pancreatic disease. \Ve speculate that this 
disorder may not be as rare as is suggested by the sporadic cases reported previously. Our 
experience suggests that the presenting features, in particular weight loss and painless 
obstructive jaundice leading to a high clinical suspicion of pancreatic cancer, is more or 
less uniform. In contrast, the individual natural history of the disease seems to vary 
substantially, ranging from a clinically unremarkable, non-progressive course to a course 
dominated by recun-ent episodes of obstructive jaundice, either secondary to benign 
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compression of the common bile duct or to lllultifocal intrahepatic bile duct stricturing. 
Obviollsly, the key question is \vhether our patients did not suffer from 'ordinary' PSC 
with a mere coincidence of idiopathic chronic pancreatitis. There ai'e several arguments in 
favor of this hypothesis. Both PSC and 'sclerosing pancreatocholangitis' mainly affect 
male patients and both conditions are characterized by cholestasis. Also, in both diseases 
morphological bile duct abnormalities are very much comparable. On the other hand, there 
are a number of significant differences. Pancreatic enlargement suggesting malignancy, 
with exocrine and endocrine pancreatic insufficiency, is rarely observed in PSC (6, 7). IBD 
was neither found in our patients nor in any of the previously reported cases (13, 22-36, 
38-42) while the prevalence among patients with PSC is at least 60% (43-47), Further, the 
mean age of 55 years at presentation in the present series and of 53 years in the literature 
cases (Table II) would be relatively high for PSC (43-47), In contrast to reported 
prevalences of semm pANCA of over 50% in PSC (48-50), none of our patients tested 
positive. Finally. marked improvements in morphological bile duct abnormalities and 
serum liver biochemistry follmving corticosteroid treatment were observed in a number of 
our patients. Such response is definitively not likely - and has not been reported - in PSC 
(51,52), Although we acknowledge that these differences with 'ordinary' PSC provide us 
\vith no more than circumstantial evidence, Illost data seem to indicate that our patients did 
not have PSC with some form of coincidental pancreatic involvement but rather suffered 
from another disease. Since the tlbrosing inflammatory process both affects the biliary 
tract and pancreas (13, 34) 'sclerosing pancreato-cholangitis' (53) may be an acceptable 
name for the condition. 
Painless obstructive jaundice secondmy to pancreatic enlargement constitutes a well-
known diagnostic problem and a reliable distinction between cancer and chronic 
pancreatitis remains difficult, if not impossible, without histological examination. The 
initial clinical presentation of sclerosing pancreato-cholangitis can be highly suggestive of 
pancreatic cancer. In this context it should be noted that none of our patients had chronic 
pain suggesting the possibility of chronic pancreatitis. In general, in approximately 5% of 
patients presenting clinically with pancreatic malignancy pancreatoduodellcctomy is 
performed for what postoperativcly appears to be a misdiagnosis (54). As illustrated by our 
experience and by other reports (II, 13, 16, 30, 34, 36, 38) patients with sclerosing 
pancreato-cholangitis may be subjected to pancreato-duodenectomy for a benign disorder. 
One way to prevent this, at least in theory. would be to deliberately aim at adequate 
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cholangiography of the entire bilhu·y tree in order to detect potential (intrahepatic) 
strictures. However, this would not prevent mis-diagnoses in case of rapid post-operative 
development of biliary strictures, a course also described previously by Stathopoulos et a1. 
(36). Furthermore, inflammatory pancreatic enlargement, mimicking carcinoma, may also 
occlir in the absence of intrahepatic biliary abnormalities (9, 11-13, 16). 
The symptomatic treatment of sclerosing pancreato-cholangitis is straightforward. Bile 
duct obstmction due to pancreatic swelling can be treated by placement of biliary 
endoprostheses and exo- and endocrine insutIiciency with pancreatic enzyme suppletion 
and antidiabetic dmgs. Experience with treatment of the underlying inflammatory disease 
process is very limited. Ideally, the aim of therapy should be to restore normal pancreatic 
function and bile flow. CutTently, the few data available suggest that the therapeutic 
response to corticosteroids can be excellent. We as well as others (23, 29, 35, 37, 42) found 
marked improvements in serum liver function tests in patients treated with corticosteroids. 
More importantly, biliary strictures disappeared or diminished in several patients and 
improved pancreatic function was observed as well. It should be noted, however, that we 
and others (22, 32, 39, 40) have also witnessed a favorable, non-progressive clinical course 
without immunosuppressive treatment. Further study of the etiology and natural course of 
the disease seems mandatory and hopefully wi11 clarify whether and when medical therapy 
is indicated and what should be the primary aim of treatment. 
The putative beneficial response to corticosteroids suggests that sclerosing pancreato-
cholangitis has an immune-mediated etiology. The reported association with Sjogren's 
disease (22, 26, 28, 29, 40), also found in one of our patients, and the remarkable 
resemblance of sialographic and cholangiographic findings (55, 56) make it tempting to 
assllme that these disorders share a common pathogenesis. It has also been suggested that 
tius disorder is part of the spectrum of 'idiopathic multifocal fibrosis' (29,35,36,41). This 
is supported by the fact that of 26 previously reported patients six also had Sjogren's 
disease, two had a fibrotic thyroid tumor, two had a retroorbital mass and two had 
retroperitoneal fibrosis (Table II). 
In conclusion, we report all ten patients with a distinct inflammatory syndrome 
involving the pancreato-biliary tract. Patients typically are males and present with 
jaundice, weight loss and endocrine ancUor exocrine pancreatic insufficiency. Imaging 
shldies usually are compatible with a diagnosis of pancreatic cancer. The clilucal evolution 
of the syndrome is highly variable. Clitucians should be aware of this condition that may 
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rnimick both PSC and pancreatic cancer. Preliminary experience indicates that there may 
be a favorable response to immunosuppressive treatment. 
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Table I: Patient characteristics at presentation. 
pat sex age weight lBD bilirubin APh liver fecal elastase-1 diabetes concomitant 
(yrs) loss (kg) (~molfl) (Ufl) histology (mg/g) disorders 
M 63 6 absent 14 536 fib:mo. ifu. pi n.a. yes 
2 M 19 >5 absent 150 569 fib:mo. ifh. pi n.a. no 
3 M 48 30 absent 126 212 flb:mo,pi <0.015 yes M.sj6gren 
4 M SO >2 clinically: no 233 473 n.a. <0.015 yes hypothyroidism 
5 M 61 20 absent 13 614 fib:mo. pi <0.015 yes 
6 M 52 7 clinically: no 108 327 ifh. pi <0.015 no 
7 M 57 12 absent 114 288 ifh. pi <0.015 (Whipple) no 
8 M 61 12 absent 47 1194 fib:mo, ifh, pi n.a. no 
9 M 46 20 clinically: no 174 269 n,s.. 0.255 no 
10 M 63 10 clinically: no 88 2190 fib:se, pi 0.022 no 
Pat: patient: n.a.: not available: IBD: inflam.matory bowel disease: APh: alkaline phosphatase: 
fib: fibrosis: ifh: interface hepatitis: pi: portal infiltrate: mo: moderate: se: severe. 
Fecal elastase concentration <0.100 mg/g indicates severe exocrine pancreatic insufficiency. 
Table ll: Ca~es reported in the litet:J.ture. 
Author Y'~ sex nge (yr) jnundice exocrine diabetes conconUlMt di~orders 
pancreatic 
insufficiency 
Waldram 1975 2 MIF 36/31 yes yes yes M.Sjogrcn / M.sjogrcn 
Sjogren 1979 M 43 ~light yes yes submandibul:;rr gland tibrosis 
Scully 1982 M 55 yes 
Jain 1983 M 41 ye~ 
Montefusco )984 F 4S yes M.Sjogren 
Thompson 1985 M 51 yes yes yes 
Ven:apuech 1986 M 63 00 yes ye~ M.Sjogren 
CI:ltk 1988 2 M 62163 yes fibrotic thyroid tumor and retroorbital wft tissue ma~s / Dupuytren 
ZoltllnU~7.ik 1988 M 37 M yes 
B='" 1989 F 30 yes M.Sjogren 
Ba~tid J990 M 78 yes yes 
Soed 1990 F 44 yes yes yes 
K:J.waguchi 1991 2 M 69/74 yes 
'-'in 1992 F 51 yes RiedeI"s thyroiditis and retroperitoneal fibrosis 
St:lthopoulos 1995 2 2M 49/27 yes 
Churoputti 1995 M 69 yes retroperitoneal fibrosis 
Beck 1996 F 59 ye~ 
Ectors 1997 M 77 yes 
PoW 1997 M 68 00 yes yes 
Nieminen 1997 M 32 yes yes M.Sjogren, pulmonary interstitial nodul:;rr infiltration~ 
Levey 1998 M 58 yes lurge hyperpla,tic ax.illary lymph node, retroorbital ma.'s 
Kazumori 1998 M 58 yes yes 
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BILE DUCT LESIONS IN PORTAL VEIN THROMBOSIS 
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Abstract 
Four patients ,,,ith portal vein thrombosis, three men of 51,45 and 31 years and one 
woman of 22 years, presented with symptoms or signs of biliary obstmctioll. Laboratory 
investigations revealed cholestasis. Cholangiography demonstrated smooth indentations of 
the common bile duct consistent with extcmal compression by collateral veins. The clinical 
course varied from spontaneous resolution of both symptoms and serum biochemical 
abnonnalities to persistent cholestasis. In two cases, surgical treatment (splcllorenal shunt 
and hepaticojejullostomy) failed due to the presence of numerous collateral veins. Biliaty 
strictures secondary to the formation of a pOlial cavemoma, so-called pOIial biliopathy, is a 
fairly unknown complication of portal vein thrombosis. Although the majority of patients are 
asymptomatic, p0l10-systemic shunt surgery or endoscopic biliaty intervention may be 
indicated in symptomatic cases. 
Introduction 
A network of collateral veins may develop in the hepatoduodenal ligament following 
thrombosis of the portal vein (1-3). Ultrasonographic imaging of tllis conglomerate of veins, 
which is called a portal cavellloma or cavemomatous transformation of the p0l1al vein, may 
produce a characteristic pichlre (Fig 1). 
The most frequent complication of p0l1al vein thrombosis is bleeding from oesophageal 
or gastric varices (1, 4) or, less common, from ectopic variccs in the duodenum or rectum 
(5), A rare and relatively nnknown complication of portal vein thrombosis, involving the 
biliary tract, will be discussed by mcans of the case historics described below. 
Case histories 
Pa/iem A, a 51-year-old male, presented with oesophageal vaticeal bleeding 20 years 
ago. Treatment consisted of a splenectomy. P0l1osystcmic shunt surgelY failed due to 
massive per-operative blood loss from collateral veins. On the basis of histological, 
ultrasonographical and angiographical examinations the diagnosis 'thrombosis of the portal 
and superior mesenteJic veins' was made. A cause could not be identified. 
Ten years ago, he presented for the first time with abdominal pain, jaundice, dark mine 
and discoloured stools. Laboratory investigations revealed cholestasis (Table I). Endoscopic 
retrograde cholangiopancreatography (ERCP) demonstrated multiple stJichlres of the 
common bile duct. A diagnosis of primary sclerosing cholangitis was considered likely. 
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Figure I. U1tra~onography of a portal cavernoma. 
'Within two weeks symptoms disappeared and serum liver tests normalized. Two years 
later, the same signs and symptoms recun·ed. At ERCP small intrahepatic stones were found 
in addition to the previously known abnOlmalities. A nasobiliary drain (Fig 2) was 
introduced for lavage of the biliary tree. Treatment had to be stopped because of the 
development of fever 24 hours later. The symptoms disappeared after antibiotic therapy and 
the patient was discharged in good general condition. After a duodenal variceal haemorrhage 
I year later and recurrent oesophageal variceal bleeding 2 ye1U"s later, endoscopic 
sclerotherapy was initiated resulting in vmiceal eradication. One year ago he presented again 
with jaundice. ERCP revealed small concrements and smoolh, undulating strictures of the 
common bile duct. Some small stones drained off after papillotomy. Just like six years ago 
the patient developed fever after biliary lavage but it disappeared as a result of antibiotic 
treatment. During the following year he was asymptomatic but semm liver tests indicating 
cholestasis persisted. Subsequently, an endoproslhesis was placed in the common bile duct 
for a period of 8 weeks. Six months later, he was asymptomatic and the semm liver tests had 
normalized. 
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Figure 2. ERCP through nasobiliar)' drain. 
Patient B, a 45-yeat'-0Id male with a histOl}' of cholecystectomy for cholelithiasis and 
pancreatojejunostomy for chronic pancreatitis, was found by ultrasonography to have portal 
vein thrombosis with cavemomatous transfonnation. Because of recurrent pancreatitis two 
years later, an ERCP was performed; smooth, undulating strictures of the common bile duct, 
consistent with venous impressions, were demonstrated (Fig 3). A year ago he complained of 
upper abdominal pain; laboratOlY examination showed cholestasis (Table I). ERCP 
demonstrated smooth nalTowing of the distal common bile duct, consistent '''itb. extemai 
compression, and slight bile duct dilatation with smail calibre changes in the proximal pali. 
A stent was placed endoscopically. Because of cholangitis due to stent clogging the 
endoprothesis had to be replaced 4 times during a period of 6 months. An attempt to create a 
surgical biliodigestive anastomosis failed because of the presence of mUltiple venous 
collaterals. Subsequcntly, two sessions of endoscopic balloon-dilatation of the distal common 
bile duct were performed but the seHnll liver tests did not improve. It is not clear whether this 
was caused primarily by compression of the distal common bile duct due to enlargement of 
the pancreatic head or biliary abnormalities secondruy to the pOlial caVCl11oma. Perhaps a 
combination of the two factors is responsible. Recently, a metal 'self-expandable' 
endoprosthesis was placed in the distal conmlOIl bile duct. 
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Figure 3. ERCP showing smooth, undulating strictures of the common bile duct. 
Patient C. a 22-year-old female, presented \vith biliary colic-like pain and vomiting. Her 
medical history had been remarkable; the following diagnoses had been established: 
'polymiritis nodosa', 'recurrent pericarditis', 'superior vena cava syndrome due to 
mediastinal lymphadenopathy', 'agenesis of the intrahepatic pm·t of the inferior vena cava' 
and 'multiple oesophageal and gastric vaIiceal haemolThages due to thrombosis of the portal, 
splenic and superior mesenteric veins. In contrast to previous investigations, laboratory 
examination showed hyperbilil1lbinaemia (Table JJ, At ultrasonography mnltiple venous 
collaterals sun'ounding the common bile duct \vere seen. ERCP showed a smooth, flexible 
nmTowing in the distal common bile duct, consistent with compression by collaterals. The 
signs and symptoms disappeared spontaneously and did not recur within the next four years. 
Patient D, a 31-year-old male, had always been healthy until he was admitted with 
abdominal pain, fever and an infIltrate in the tight quadrant 9 years ago. Laboratory 
examination showed, in addition to an elevated erythrocyte sedimentation rate of 75 
Hun/hour and leucocytosis of 24.9x109 II, liver abnonllalities indicative of cholestasis (table 
1). Blood cultures were positive for streptococci. Ultrasonography showed portal vein 
tluombosis with a portal cavernoma. ERCP demonstrated biliary abnormalities comparable 
to those seen in patients A and B (Fig 2, 3). Despite extensive investigations no explanation 
for this clinical picture was found. The patient recovered spontaneously and the serum liver 
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tests normalized within a peliod of 6 months. T,vo years later he presented with symptoms of 
acute appendicitis. At laparotomy a retrocaecal inflamed appendix with adhesions to 
sun·ounding stl1lctures was found. Microscopical examination of the excised appendix 
showed appendicitis with perforation and peritonitis. The patient remained asymptomatic for 
the next 9 years. Retrospectively, it seems plausible that the fust period of abdominal 
symptoms and septicaemia was probably also the result of appendicitis. The septicaemia may 
have caused thrombosis of the portal vein and, subsequently, the bile duct lesions. 
Table I. Senull liver tests in the 4 patients with portal biliopathy at the time of diagnosis. 
upper limit of normal patient 
A B C D 
total bilirubin 17 f1moVi 149 90 28 10 
alkaline phosphatase 117 Ull 413 2765 64 908 
y-giutamyltranspeptic\ase 49 Ull 322 627 29 512 
aspartate aminotranspherase 37 Ull 127 211 15 26 
alanine aminotranspherase 41 Ull 253 197 10 75 
Discussion 
Portal hypertension secondary to biliary liver diseases, such as primary biliary 
cirrhosis and primary sclerosing cholangitis, is a well-known, frequently occurring finding. 
In contrast, biliary abnormalities resulting from (formation of venous collaterals in) portal 
hypertension are rare and relatively unknown. The patients had portal vein thrombosis in 
all published cases. 
Bile duct lesions in portal vein thrombosis, also called 'portal biliopathy' (6), is rarely 
seen in the westem world since the prevalence of portal vein thrombosis is low (I). In 
contrast, in Asian countries such as Inciia, portal vein thrombosis is mllch more common and 
is one of the most important causes of portal hypel1ension (7). The reason for this 
considerable difference in prevalence is unknown. In more than 90% of cases in an Indian 
study, a cause could not be found (8). Cholangiographical studies show that biliary 
abnormalities are often present (80-100%) in these patients (8-10). The vast majority of these 
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patients remain asymptomatic. Mild to moderate elevations of serum bilirubin, alkaline 
phosphatase and transaminase levels are often found (9, 10). However, severe complications, 
such as cholestatic jaundice, cholangitis, abdominal pain (6, I I, 12) and secondruy biliruy 
cirThosis (11), can occur and filay even be the first manifestation of portal vein thrombosis 
(la, 11). As demonstrated by the course of disease in some of our cases, cholestasis may be 
transient. TIlls could result from the passage of biliaty sludge or concrements that were 
caused by the bilim)' sttictures. Other possible explanations could be that biliary compression 
decreases over time due to the development of new venous collaterals elsewhere or due to 
initial other problems, such as septicaemia as in patient D. 
Two, not mutually exclusive, explanations for the pathogenesis of tillS disorder have 
been suggested in literature. In portal vein thrombosis pOliopOlial collaterals may develop 
around the occluded part of the vein; tIus phenomenon can be considered a natural adaptation 
and by-pass mechanism aimed at the maintenance of potial perfusion of the liver and 
reduction of the venous pressure in the venous splanchnic compatiment. Collaterals that 
sUlTound the bile ducts may lead to bile duct compression (8, 13). The second hypothesis is 
that thrombosis also occurs in the efferent veins and afferent artelies of the biliary tree during 
thrombotic occlusion of the portal vein. This might lead to ischaemic damage to the biliruy 
ducts with subsequent development of fibrosis and strichlres (la, 11). 
Imaging studies may show involvement of the entire biliary tree, but the abnormalities 
are usually limited to the COlllinon and left hepatic bile ducts (8, 10). Smooth, undulating 
narrowing is seen in the most ch:U'acteristic cases. Sttichll'es, segmental dilatation, 
il1'egulmities of the bile duct wall, pruning of intrahepatic bile ducts (8, 10) and concrements 
(6,8, II) sometimes in combination with calcification of the portal cavernoma (12) can also 
be found. The abnonnalities may mimic the ones that can be found in plimary sclerosing 
cholangitis or cholangiocarcinoma (10, 14). Therefore, the terms 'pseudo-sclerosing 
cholangitis' or pseudo-cholangiocarcinoma' (9) may be used to desclibe the abnormalities. 
The biliat)' lesions in portal biliopathy can be distinguished in paliicular from the 
abnormalities in primary sclerosing cholangitis by the smoother, undulating nalTowing of the 
bilial)1 lumen (8, 10). Sometimes it is possible to visualize the collaterals in the wall of the 
bile duct by means of ultrasonography (Fig 4), 
Experience with the therapeutic possibilities for this disorder is limited. The constmction 
of a surgical shunt, presumably the most rational approach, may result in complete 
disappearance of the bilimy abnormalities (II, 15-17). Tecluucally, however, this is not 
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always feasible. If other veins, in addition to the pOlial vein, are also occluded, shunt surgery 
may be impossible. Finally, biliruy abnonnalities can persist after the construction of a shunt. 
This could be an argument for the hypothesis that some patients have fixed (possibly 
ischaemic) strictures. In these cases, balloon-dilatation (10) or hcpaticojejullostomy (6) may 
be indicated in second instance. Endoscopic placement of a stent (12-14, 18) or balloon-
dilatation (11) may be successful, with or without additional extraction ofbilimy stones (15). 
One should be aware of the problems and dangers of a surgical approach. Surgical 
exploration of the hepatoduodcnal ligament and identification of the bile ducts can be 
associated with significant blood loss due to extensive vasculmisation (12), sometimes with a 
fatal outcome (6). If biliary tract surgery is considered, this should preferably be performed 
after pOliai decompression (6). 
POlial biliopathy should be included in the differential diagnosis for patients with pOlial 
vein thrombosis and cholestasis. A non-intervention policy secms justified for asymptomatic 
patients. For symptomatic patients, surgical or endoscopical treatment may be chosen, 
depending on the extent of the thrombosis and the type of the biliary lesions. 
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Figure 4, Intraluminal ultra~onography within the common bile duct showing venous collatcrals adjacent 
to the bile duct wall. 
Table 2. Most important causes of biliary strictures (19), 
Primruy sclerosing cholangitis 
Ischaemia of bile ducts 
Previous biliary surgety 
'Oraft-versus-host'disease 
Rejection of liver transplant 
Infusion of cytotoxic medication in the hepatic :al1ery 
Cholangiocarcinoma 
Choledocholithiasis 
AIDS-related cholangiopathy 
Sclerosing pancreato-cholangitis (20) 
P0l1al vein thrombosis 
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Abstract 
In PBC the rate of disease progression varies considerably between individuals. On the 
basis of serological subtyping 4 AMA profiles (A, B, C and D) can be defined. The 
intriguing finding of previous studies that profile C/D is associated with a progressive course 
and profile AlB with a benign, non-progressive course is still a question of debate. \Ve 
investigated whether AMA profiles predicted the clinical course for a cohOit of Dutch PBe 
patients. SCHun samples from 38 AMA-positive progressive patients (34 female; 2 samples 
per patient; median interval 2.5 yrs), 31 M1A-positive patients without evidence of 
progression for at least 6 years (26 female), 5 AMA-negative PBC patients, 5 Iloll-PBC 
decompensated cinhotics and 5 healthy volunteers ,vere assessed. Progressive PBC was 
defined as the occurrence of liver transplantation (11:::;15), liver-related death (n=3), variceal 
bleeding (n=3), ascites (n=4) and histological cilThosis (n=I3). AMA profJles were 
determined without knO\vledge of the clinical data. In the progressive AMA-positive group, 
13% (n=5) had profile AlB, 84% (u=32) had profile CID; I case was only AMA-positive in 
illUl1tmofluorescence. A change from profile A/B to profile C/D or vice versa was not 
observed. In the non-progressive group, 13% (n=4) had profile AlB, 77% (n=24) profile 
CID; 10% (n=3) had no profJle. An AMA profile was not detellllined for the 15 AMA-
negative control samples. 
In conclusion, AMA profile testing yields reliable, reproducible results. However, our 
results do not support the suggestion that AMA proftles should be used as independent 
indicators of the ultimate clinical outcome of PBC. TIlC divergent results of tlils and previous 
studies may be explained by the selection of different PBC patient populations. 
Introduction 
Demonstration of seHlIH antimitochondIial antibodies (AMA) fonl1s the corner stone of 
the diagnosis of primary biliary cirrhosis (PBC) (1-4). In addition to the diagnostic 
significance of AMA, prognostic value has been attributed to four PBC-specific AMA-
subtypes which i'ue based on the presence of anti-M2, -M4, -M8 and -M9 antibodies, 
respectively (5-8). Among PBC patients with anti-M4 andlor anti-M8 antibodies (AMA 
profile C/O) the course of the disease was progressive, leading to cirrhosis and hepatic 
decompensation, whereas the course among patients without anti-M4 and anti-M8 antibodies 
(AMA proftle AlB) was found to be non-progressive for at least 10 years (9-12). 
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Up to now, AMA-subtype determination was not considered a potential tool for 
assessment of the prognosis. This may at least pattly be related to the reported inability of 
other groups to reproduce the Oliginallaboratory results (13-15). The aim of tillS study was to 
COnfll111 the previously reported prognostic value of AMA-subtypes for a heterogeneous 
population of Dutch PBC patients using the original laboratory facilities. 
Patients and methods 
From each of 38 AMA-positive PBC paticnts with progressive disease two serum 
samples were collected. The diagnosis of PBC was based on a combination of positive 
anti mitochondrial antibodies (AlvIA) at a titre of ;;:::1 :40 as shmvn by indirect 
immunofluorescence (IF), cholestatic Sel1Ull liver tests, and compatible/diagnostic 
histological features. Progression was defined as: liver transplantation (for stage IV disease), 
liver-related death, variceal bleeding, ascites or histological stage IV disease. The main 
clinical features of these patients are in listed in table 1. \Ve tested two samples per patient in 
order to detennine whether the profile remains the same over timc. The interval between the 
two samples varied from one day to 10 years (median 2.5 years). Samples from transplanted 
patients were obtained before the procedure. In theory, and according to previous studies, the 
AMA profiles of sera from this group were expected to be C or D in (nearly) all cases. 
In addition, serum samples from 31 AMA-positive non-cirrhotic PBC patients, \"1'110 had 
remained clinically stable for at least 6 years. were analysed. TIle AMA profile of a 
proportion of these sera was expected to be A or B. Fm1hermore, serum samples from five 
PEC patients who tested AMA-negative with IF, five non-PEC patients with decompensated 
cilThosis (alpha I-antitrypsin deficiency n= I, primary sclerosing cholangitis n=2 and 
alcoholic liver disease n::::2) and five healthy volunteers were assessed. The main 
charactelistics of these patients and volunteers are listed in table II. Thus a total of 122 serum 
samples were collected at the University Hospital Rotterdam and transported frozen to the 
Eberhard-Karls-University Hospital TUbingen, Germany, for analysis. 
The AMA-subtypes were determined according to previously desclibed techniques (12), 
without any knowledge about the cOlTesponding patient. Samples were only identified by a 
number. The samples were tested for the presence of antinuclear antibodies (ANA) and 
smooth muscle antibodies (SMA). The senllll samples were assigned an AMA profile as 
follows: profile A was defined as only anti-M9 positive in ELISA and Western blot, promc 
B as anti-M2 positive in complement fixation test (CFf) and/or ELISA, inespective of the 
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presence or absence of anti-M9, profile C as anti-M2 in association with anti-M4 and/or anti-
M8 in ELISA, irrespective of the presence or absence of anti-M9 and profile D as anti-M2 in 
association with anti-M4 and/or anti-M8 in ELISA and CFT, in'espective of the presence or 
absence of anti-M9. Subsequently the AMA profile results were analysed in relation to the 
presence or absence of PBC and the clinical course. 
Results 
Of the 69 AMA-positive PBC patients, 81 % had profile C/D, 13% had profile AlB, 3% 
were only AMA-positive in IF and 3% were AMA-negative in both IF and ELISAlCFT (Fig 
I). 
AMA·profi!e NB 
81,0% AMA·negative 
AMA·profile C/O 
AMA·posilive in IF 
Figure 1. Distribution ofAl-.·lA profiles among 69 MiA-positive (IF) PBC patients. 
A Iltibody jJmfiles for 38 PBe patients with a pmgressive course 
Thirty-two (84%) of these patients were found to have AMA-profile C/D and 5 (13%) 
profile AlB (Table III). One patient tested only AMA-positive in IF, whereas ELISA as well 
as eFT were negative for all AMA-subtypes in both samples. For patients with profile AlB 
or without an AMA profile, progression was characterized by liver-related deatb, liver 
transplantation for end-stage cinhotic disease and histologically documented cinhosis in two 
cases each. AMA profile A was found for one patient '''ith stage IV disease while the other 
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four had profile B. The AMA profile remained stable over time, since a change from profile 
AlB to profile C/O or vice versa was not observed. Eighty percent (4 of 5 patients) and 60% 
of the profile A/B patients tested positive for ANA and SMA, respectively. Eighty-four 
percent and 81 % of the profile C/O patients tested positive for ANA and SMA, respectively. 
Alltibody pmfilesfor31 clillically stable AMA-positive PBe patients 
Twenty-four (77%) of these patients were found to have prome CfD (Table Ill), 13% 
had profile AlB. Two patients were AlvlA-negative in IF, ELISA and CFT, and one patient 
was only AMA-positive in IF. Fifty percent and 75% of the patients with profIle AlB tested 
positive for ANA and SMA, respectively. Thirty-three percent and 88% of the patients with 
profile C/O tested positive for ANA and SMA, respectively. 
A ntibody profiles for 15 negative COlltro/s 
All AMA-negative PBC patients (n=5), non-PBC decompensated cinhosis patients 
(n=5) and healthy volunteers (n=5) were AMA-negative in both IF and ELISA/CFT. 
Discussion 
In this study it appeared that 13% of patients with clinically progressive PBC have 
antimitochondrial antibodies of profIle AlB, the proflle that was previously found to predict a 
non-progressive course (12). Therefore we could not continl1 that a progressive course is 
marc or less restricted to patients exhibiting AMA-proftle CfD. Furthennore, in this study the 
vast majority (81%) of AMA-positive PBC patients had prome C/O, thereby the potential 
impact of the AMA profile on the selection of patients for follow-up and evaluation of 
experimental treatment modalities may be relative. 
A number of factors may explain the discrepancy in the tindings between the present and 
previous studies. Selection bins seems to be the most likely explanation. TIle University 
Hospital Rotterdam is a tertiary referral centre for patients with liver disease in the 
Netherlands and therefore attracts proportionally more PBC patients with advanced liver 
disease, while the German PBC population (12) was partly chosen from screening 
prograllunes for autoantibodies. The fact that a relatively high proportion of stage I and II 
patients (89%) was included in the study by Klein et al. (12) with a consequently more 
favourable five-year survival rate compared to other PBC COh0l1 studies (16-19) fm1her 
SUPP0l1s the suggestion that the study populations were not comparable. Secondly, other 
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factors besides PBC itself may influence the rate of disease progression. The majority of 
patients with a progressive course and AMA profile AlB also tested positive for ANA andlor 
SMA, so other (overlapping) autoimmune features may have contributed to the final clinical 
outcome. However, it should be noted that all patients with a progressive course had proven 
PBC according to established diagnostic criteria and the majority of stable patients also 
tested positive for ANA and/or S:MA. Finally, clinical outcome is not equivalent to clinical 
course. The retrospective design of the present study does not allow us to draw conclusions 
about whether AMA proftles differentiate between a rapid and a slow, but progressivc, 
course. Observations during more prolonged foHow-up, in particular of the large German 
population (12), may fmther elucidate this intriguing question. A further limitation of the 
design of the present study is the fact that sensitivity, specificity and predictive value of the 
AMA profile test could not be calculated since it is not known whether PBC patients who 
have been clinically non-progressive for at least six years will remain stable in the future. 
Previous rep011s (13-15) have raised considerable doubt on the validity of anti-M4 and 
anti-M9 antibody determinations in PBC. Our data demonstrate that the reproducibility and 
specificity of AMA profile deterl11inations can be excellent. None of the AMA-negative 
controls was assigned to an AMA profile group and MiA profiles remained unchanged over 
time. 
The ratc of disease progression varies considerable among individual PBC patients. 
Mathematical prognostic models, such as the Mayo model (20), use time-dependent vadables 
to predict the clinical course and consequently indicate the timing of liver transplantation. In 
the early stages of PBC, however, these models cmmot predict for each patient whether the 
course will be relatively benign or progressive. Previous studies on AMA and disease 
progression provided no evidence that AMA titres or the absence of AMA is related to 
disease progression (21, 22) 
In conclusion, this study could not confinl1 that AMA profiles can be used as a reliable 
indicator of clinical outcome in PBe. The intriguing hypothesis that the prognostic potential 
of AMA depends on patient selection criteria requires further study. 
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Table 1. Clinical features of progressive PBC patients. 
Progressi,'e PEe (1/) 
Sex(MlF) 
Age (yrs) at sample 1; median (range) 
Age (yrs) at sample 2; median (range) 
Progression defined as: 
- liver transplantation (n) 
- liver-related death (n) 
- ascites (n) 
- variceal haemOlThage (n) 
- stage IV biopsy (n) 
81 
38 
4/34 
56 (31 - 69) 
58 (32 - 72) 
15 
3 
4 
3 
13 
Table II. Characteristics ofnon~progressive PBC patients, non~PBC decompensated 
citThosis patients, AMA-negative PBC patients and healthy volunteers. 
NOll-progressive PBC (II) 
sex (MIF) 
Age (yrs); median (range) 
NOIl-PBe decompensated cirrhosis (11) 
sex (MIF) 
Age (yrs); median (range) 
AMA-llegative PBC (II) 
sex (M/F) 
Age (yrs); median (range) 
Healthy ,'olllllteers (11) 
sex (MIF) 
Age (yrs); median (range) 
Table Ill. The AMA profiles fonnd for the five categories. 
sera obtained from profile AlB n profile C/D n 
(%) (%) 
progressive PBC 5 (13%) 32 (84%) 
non-progressive 4 (13%) 24 (77%) 
PBC 
AMA-negative 0(0%) 0(0%) 
PBC 
nOll-PBC cinhosis 0(0%) 0(0%) 
healthy volunteer 0(0%) 0(0%) 
* AMA was only positive in immunofluorescence. 
31 
5/26 
56 (29 - 72) 
5 
1/4 
41 (39 - 53) 
5 
1/4 
58 (43 - 69) 
5 
0/5 
26 (22 - 48) 
no AMA profile n 
(%) 
1 (3%)* 
3 (10%)** 
5 (100%) 
5 (100%) 
5 (100%) 
**One patient was only AMA-positive in immunofluorescence; two tested AM A-negative. 
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Abstract 
The incidence and prognostic significance of major clinical complications in PSC, 
including the development of dominant bile duct strictures, cholangiocarcinoma and 
colorectal carcinoma, cholangitis and de-llovo inflammatory bowel disease (JBD), arc 
poorly documented. These aspects were assessed in a cohort of 163 patients (67% males; 
median age 33 (12-72) years) followed for a median period of 6.6 (0.04-21) years. At the 
time of diagnosis 59% had associated IBD. Median transplantation-free survival was 13.5 
years; there was a clear difference between asymptomatic (15.3 years) and symptomatic 
patients (7.7 years) (p=0.0002 log-rank test). The 10120-year risks for dominant bile duct 
strictures and choiangiocarcinoma were 29135% and 7117%, respectively. The IO-year risk 
for de-novo ISO was 26%. For the total cohort of patients and those with IBD at 
presentation, the IO-year risks for colorectal cancer \vere 9% and 14%, respectively. The 
I0l20-year risk for both colorectal carcinoma and cholangiocarcinoma was 15/25%. 
Univariate analyses shO\ved that higher age, cirrhosis, symptomatic presentation, higher 
serum bilirubin and lower senllll albumin levels predicted shorter transplantation-free 
survival. Multivariate analysis revealed that age (RR 1.04; 95% CI 1.02-1.06) and 
symptomatic presentation (RR 2.5; 95%-CI 1.4-4.5) were independent prognostic variables 
of decreased transplantation-free survival. Time-dependant analyses showed that the 
development of dominant bile duct strictures (RR 2.6; 95%-CI 1.2-5.6) or cholangitis (RR 
7.3; 95%-CI 2.9-18.3) was a predictor of a high risk of dying. These results underline the 
progressive character of the disease and the markedly decreased life expeetaney of affected 
patients. A more favorable prognosis can be expected in the absence of symptoms of liver 
disease, e.g. when PSC is diagnosed in the context of IBD associated with liver test 
abnormalities. Patients with PSC have a high lifetime risk for developing bile duct and 
colerectal cancer. 
Introduction 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease 
characterized by fibrosing inflammatory strictudng and gestmction of extrahepatic and/or 
intrahepatic bile ducts (I). The disease may progress to biliary cirrhosis, with 
complications arising from hepatic decompensation and portal hypertension. In addition, 
during the course of the disease more specific complications may occur, including the 
development of 'dominant' bile duct strichlres (2, 3), bacterial cholangitis (1) and bile duct 
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cancer. The latter is by far the most feared complication with a reportcd survival rate 
which is independent of liver transplantation and does not exceed 20 percent (4-6). Since 
the majority of patients also suffer from long-standing infiammatOlY bowel disease (IBD), 
the development of colerectal cancer constitutes another life-threatening problem. 
Several studies have reportcd on thc natural history and prognostic determinants of 
(transplantation-free) survival (7-11). The risk and prognostic significance of dominant 
bile duct strictures and bacterial cholangitis, however, have not been denned. In addition, 
relatively little is known about the lifetime risk for bile duct canccr (12, 13) and colorectal 
cancer (14). 
Therefore, the aim of the present study \vas to bettcr denne the natural history of PSC, 
focussing on the long-term risks and prognostic significance of disease-specific 
complications. 
Patients and methods 
One hundred and sixty three PSC patients were included in the study. This cohort 
consisted of all patients seen at the University Hospital Rotterdam in the period 1980-1998 
and all patients who participated in a prospective cohort study in the Netherlands in thc 
period 1990-1998. The diagnosis of PSC was based on typical findings on endoscopic 
retrograde, percutaneous transhcpatic or peroperative cholangiography (15) or the presence 
of characteristic histologic liver abnormalities (peri-cholangiolar 'onion-skin' fibrosis (16» 
in combination with serum liver lesls indicating choleslasis and the presence of lED. 
Small-duct PSC was diagnosed whcn cholangiography was performed but did not reveal 
diagnostic biliary abnormalities in the presence of the triad lBO, cholestatic senllll liver 
profile and characteristic livcr histologic abnormalities. Patients with bile duct 
abnormalities possibly attributablc to such causes as previous bile duct surgery, ischemia, 
portal vein thrombosis or sclcrosing pallcreato-cholullgitis (17) \vere excluded. Patients 
presenting with one of the following symptoms or signs which were the reason for 
initiating subsequent diagnostic studies wcre classified as symptomatic: pmritus, fatigue, 
jaundice, cholangitis, ascites, variceal bleeding, hepatic encephalopathy and 
cholangiocarcilloma. 
A dominant bile duct stricture was defined as a cholangiographically documented, 
marked stricture in either the common bile duct or one of the main hepatic ducts, 
diagnosed in the context of recent or aggravation of jaundice. A biliary stricture was not 
86 
regarded as 'dominant' when choiangiocarcinoma was subsequently diagnosed within a 
period of twelve months. Follow-up cholangiography was not routine. Diagnosis of 
colorectal carcinoma and cholangiocarcinoma was based on histological studies. 
Statistical analysis 
For the purpose of this study follow-up was considered to start at the time PSC was 
diagnosed. Data were collected until December 1998. Primary end-points were death and 
liver transplantation. Secondary end-points were cholangiocarcinoma, colorectal cancer, 
dominant bile duct stricture, bacterial cholangitis and de 110VO IBD. Transplantation-free 
survival and the incidence of secondary end-points were computed by the Kaplan-Meier 
method and compared between groups by means of the log-rank test. 
The following factors, which were considered to have potential prognostic 
significance, were evaluated by univariate analysis: age, sex, symptomatic presentation, 
cilThosis, IBD, serum bilimbin, albumin, aspartate aminotranspherase CAST), alanine 
aminotranspherase CALT), immunoglobulin G, creatinin, alkaline phosphatase CAPh), 
ganuna-glutamyltranspeptidase (,<:IT), prothrombin time (PT) and anti-thrombin-III levels. 
Factors in univariate analyses with a p-value <0.20 were assessed by multivariate analysis. 
Multivariate Cox analyses with the backward elimination procedure werc used to examine 
baseline prognostic factors and time-dependant prognostic factors, i.c. dominant bilimy 
strictures and cholangitis. A p-value <0.05 was considered statistically significant. 
Results 
In the study period 163 patients with PSC wcre diagnosed and followed for a median 
period of 6.6 (0.04-21) years. Clinical, biochemical and histological baseline 
characteristics arc listed in table I. For the 2.5% of the patients who werc lost to follow-up 
data were censorcd at the time of last contact. One hundred and thirteen patients (69%) 
were seen at least once at the University Hospital Rotterdam. For 90% of the patients 
diagnosis of PSC was based on typical cholangiographic abnormalities ("large duct PSC") 
while 4% were classified as "small-duct PSC". In 6% of the cases cholangiography was 
not performed or was unsuccessful, and the diagnosis was based on characteristic 
histologic lesions in combination with semm liver tcst abnormalities and the presence of 
lBD. One hundred and nine of 163 patients (66.9%) were male. The median age at 
diagnosis was 30.5 years (12-72) for males and 40 (14-59) years for females (p=0.054). At 
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the time of diagnosis, five patients had undergone colectomy for IBD. Jaundice was the 
presenting symptom in 27% of the cases; overall, for 37% of the patients signs and 
symptoms, as listed in table II, were the reason for initiating diagnostic studies. 
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Figure I. Kaplan-?o.'leier curves showing the probability of surviving free of liver transplantation for all 
patients (thin line) and for those who were asymptomatic or symptomatic at presentation. Probability of 
transplantation-free survival was significantly higher for asymptomatic than for symptomatic patients 
(po O.OO02). 
COlli"' of PSC 
Median transplantation-free survival for the entire cohort was 13.5 years (Fig 1). 
Nineteen patients died, 17 from causes clearly related to either PSC or lBD (table III). 
Liver transplantation was performed in 28 patients. Prognosis for patients with 
asymptomatic disease at diagnosis was markedly better than for those with symptomatic 
disease: median transplantation-free survival 15.3 versus 7.7 years, respectively 
(p=O.0002). The presence or absence of cirrhosis was found to be another significant 
prognostic factor according to univariate analysis (Fig 2). 
One patient presented with choiangiocarcinoma and 8 developed this malignancy 
during follow-up. In one of these cases cholangiocarcinoma was an incidental tlnding at 
transplantation. The risk for cholangiocarcinoma at 10 and 20 years was 7% and 17%, 
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Figure 2. Kaplall~IVfeier curves showing the probability of surviving free of liver transplantation for 
patients with and without cirrhosis at presentation. Probability of transplantation-free survival was 
significantly higher for those without cirrhosis than cirrhotic cases (p=O.OI). 
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Figure 3. Kaplan-Meier curves showing the actuarial incidences of choiangiocarcinoma (eca) and 
colorectal cancer (cre) in the cohort of 163 patients. 
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Figure 4. Actuarial cumulative incidence of dominant bile duct strictures from time of diagnosis PSc. 
respectively (Fig 3). The lO-year risk for colorectal cancer was 9% (Fig 3) for the total 
cohort and 14% for patients with concurrent IBD (11=95) at diagnosis. Colorectal cancer 
was only found in patients already known to suffer from IBD at the time PSC was 
diagnosed. The 10 and 20-year cumulative incidences of colorectal and bile duct cancer 
were 15% and 25%, respectively. 
DUling follow-up 7 out of the 45 patients, who were initially found to be free of IBD 
as indicated by colonoscopy, developed IBD; the to-year incidence of de novo IBD ,vas 
26%. 
The risk of developing dominant biliary strictures was 29% after 10 years and 35% after 20 
years (Fig 4). The majority of 29 patients who developed dominant strictures were treated 
endoscopically with temporary placement of biliary endoprostheses (n=23) or endoscopic 
balloon dilatation (n=2). Endoscopic therapy failed technically in one case. In the 
remaining tlnee patients therapy consisted of hepaticojejunostomy, percutaneous biliary 
treatment or ursodeoxycholic acid. 
The 10 and 20-year risks for bacterial cholangitis were 19% and 29%, respectively. 
Multivwiate alld time-dependant analysis of tml1splalltatioll-jree slIl1'ival 
Age, symptoms at presentation, cirrhosis and serum levels of bilimbin and albumin 
were baseline factors with a predictive value according to univariate analyses. Multivariate 
analysis revealed that both age and symptomatic presentation had an independent 
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prognostic value (table IV). Time-dependant nuiltivariate analyses demonstrated that the 
development of dominant biliary strictures and cholangitis were independent significant 
prognostic factors. Combined analysis of the factors predictive according to multivariate 
and time-dependent assessments showed that age, symptomatic presentation and the 
development of dominant biliary strictures (borderline) and cholangitis were all of 
prognostic significance for future liver transplantation or death (table IV). 
Discussion 
The results of this long-term cohort study of PSC show that the course of the disease is 
characterized by relatively frequent characteristic complications, including the 
development of dominant bile duct strictures, cholangitis and choiangiocarcinoma. These 
biliary complications were found to have negative prognostic significance. \Ve confirmed 
previous findings that symptomatic disease, the presence of cirrhosis, elevated serum 
bilirubin and lowered serum albumin levels and high age at presentation were all predictors 
of a high risk of dying or needing liver transplantation (7-11). 
The problem of dominant biliary strictures in PSC has been well described (3, 18, 19) 
but data on the risk for tIus complication has not been reported previously. \Ve found that 
over a 20-year period, about one-third of all patients can be expected to develop 
symptomatic, major biliary strictures. The present study suggests that, despite therapeutic 
interventions, these strictures seem to be associated with a subsequent unfavorable course. 
In this context it should be noted that among the 28 patients undergoing liver 
transplantation dominant strictures as such were not a primary reason for transplantation. 
In only two cases was the presence of donunant strictures considered to be one of the 
significant reasons for placing a patient on the waiting list. 
The OCCUlTence of cholangitis during follow-up had a clear negative prognostic impact. 
This finding may pat1ly be explained by the fact that recurrent cholangitis was one of the 
reasons for transplantation in five of the 28 transplant recipients. However, reCUlTent 
cholangitis was never the sole or primary indication for liver transplantation. 
Median transplantation-free survival for our cohort of patients of 13.5 years was 
slightly better than previously reported values of approximately 12 years (7, 8, 10). The 
higher proportion of patients (63%) diagnosed following the detection of serum liver test 
abnormalities without the presence of clear clinical signs or symptoms in the present series 
compared to the Mayo (21 %) (7), King's College (16%) (8) and Swedish (44%) (10) series 
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may explain this smalI difference. The median serum bilimbin level of 31 ,.uHolli in the 
Mayo clinic cohort (7), which was twice as high as that for our patient group, supports this 
explanation. 
Data on the risks for bile duct and colorectal cancer in PSC is scarce. Parges et al. 
reported a 10-year risk for cholangiocarcinoma of approximately 30% for a group of 51 
PSC patients (12), whereas Kornfeld et al. found a IO-year risk of 11% (13). In the latter 
study the large majority of tumors were detected within two years of the diagnosis of PSC. 
In contrast, we found a more gradual pattern of incident new cases over a period of 20 
years, with 10 and 20-year risks of7% and 17%, respectively. 
The 10-year risk for colorectal cancer for the entire cohort was 9%, \vhich was 
substantially higher than the 4% previously reported by the Mayo Clinic group (14). 
Differences in patient popUlations, in particular in the proportion of patients with previous 
colectomy, may account for these diverging results. Comparison of our findings with the 
results of other studies (20-22) that have assessed the risk for colorectal cancer in PSC is 
difficult because these studies used a combined end-point of both colorectal dysplasia and 
cancer. 
In conclusion, the results of this study underline that PSC frequently mns a progressive 
course. Affected patients, in particular older patients presenting with already advanced 
disease, have a markedly decreased life expectancy. Prognosis is considerably more 
favorable for patients presenting without symptoms of liver disease, a situation which is 
common since diagnostic studies frequently are undertaken following the detection of 
biochemical liver test abnormalities in the presence of IBD. The occurrence of typical 
PSC-specific complications, such as dominant biliary strictures and cholangitis, is 
associated with decreased transplantation-free survival. Patients with PSC catTy a high 
lifetime risk for cholangiocarcinomu or colorectal cancer. 
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Table I. Clinical, laboratory and histologic baseline characteristics of the cohort 
of 163 PSC patients. 
Age (mean, range) in years 
Male I female (n) 
No cirrhosis I cirrhosiss (n) 
IBD (%) 
no* 
ulcerative colitis 
Crohn's disease 
undeterminate colitis 
Previous colectomy (n) 
Bilimbin (~ll1olll), normal <17 
Albumin (gil), normal >35 
APh (uti), normal <75 
AST (uti), normal <30 
§ histology available for 131 patients. 
* endoscopically verified in 67.2% of cases. 
lBD: inflammmatory bowel disease. 
35.1 (12-72) 
109154 
108/23 
41.4 
37.0 
11.7 
9.9 
5 
15.5 (4-307) 
41.1 (21-52) 
294 (35-2325) 
55 (4-918) 
Laboratory values of serum tests expressed as median and range. 
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Table II. Type of presentation leading to diagnosis of PSC (n=160). 
Symptomatic presentation (n (%» 
jaundice 
cholangitis 
jauudice+cholangitis 
ascites I variceal bleeding 
cholangiocarcinoma 
pmrihls or fatigue 
Asymptomatic presentation (n (%» 
liver test abnormalities and IBD 
liver tcst abnormalities, no IBD 
coincidental 
Information not available for 3 patients. 
Table III. Causes of death of 19 PSC patients. 
Cause 
Cholangiocarcinoma 
Hepatic failure 
Variceal bleeding 
Colorectal cancer 
Peritonitis/appendicitis 
Sepsis (following colectomy for UC) 
UnknO\vn 
94 
59 (36.9%) 
43 (26.9%) 
2 (1.3%) 
I (0.6%) 
I (0.6%) 
1(0.6%) 
II (6.9%) 
101 (63.1%) 
63 (39.4%) 
34 (21.3%) 
4 (2.5%) 
IIlImber o/patients 
7 
6 
2 
Table IV. Analysis of prognostic factors of transplantation-free survival. 
U"ivariate II (SE) RR 95%-CI p-value 
age 0.04 (0.01) 1.04 1.02-1.06 0.000 
symptomatic presentation 1.00 (0.30) 2.73 1.51-4.93 0.001 
cirrhosis 0.72 (0.37) 2.05 0.99-4.23 0.05 
bilimbin 0.006 (0.002) 1.01 1.002-1.Ql 0.002 
albumin -0.067 (0.025) 0.94 0.89-0.98 0.007 
Jlll1ltivariate 
age 0.04 (0.01) 1.04 1.02-1.06 0.001 
symptomatic presentation 0.90 (0.30) 2.45 1.35-4.46 0.003 
Tim e-l/ epelll/allt 
dominant stricture 0.97 (0.39) 2.64 1.24-5.62 0.01 
cholangitis 1.98 (0.47) 7.27 2.89-18.3 0.000 
Combined tim e-dep +111 1Iltivllr. 
dominant stricture 0.73 (0.39) 2.07 0.96-4.48 0.06 
cholangitis 1.71 (0.52) 5.54 1.99-15.4 0.001 
age 0.03 (0.01) 1.03 1.01-1.05 0.01 
symptomatic presentation 0.95 (0.31) 2.59 1.41-4.77 0.002 
p: regression coefficient, SE: standard error, RR: relative risk, CI: con11dence interval. 
Appendix 
The other members of the Dutch multicenter PSC study group are: DJ. Bac, Ikazia Hospital, Rotterdam; 
M.CJ.M. Bee;;;, Overvecht Hospital, Utrecht; J. van Hattum, KJ. Yan ErpecuJll, University rvfedical Center 
Utrecht; J.D. van Bergeijk, R.MJ. Witteman, Hospital 'De Gelderse Vallei', Wageningen; L.GJ.B. Engels, 
Maasland Hospital, Sittard; A.C Hoek, Van Weel-Bethesda Hospital, Dirksland; P. Spoelstra, D.P.F. van 
Haute, Ivledical Center Leeuwarden; R.W. de Koning, Canisius-Wilhelmina Hospital, Nijmegen; 1'I.C1-1. 
Rijk, Hospital 'De Baronie', Breda; S.W. Schalm, University Hospital Rotterdam; J. Scherpenisse, Reinier 
de GraafHospital, Delft; i'vI. Schrijver, Bronovo Hospital, Den Haag; J,W. de Bmijne, Carolus Hospital, Den 
Bosch; W.N,H.i'vl. Sluilbergen, St. Elisabeth Hospital, Tilburg; T.G, Tan, S1. Streekziekenhuis l\·liddell-
Twente. Hengelo; A,J,P, vall Tilburg, Sf. Franciscus Hospital, Rotterdam; R.A. de Vries, Rijnstate Hospital, 
Amhem; F.J.W. ten Kate, Academic Medical Center, Amsterdam. 
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Part III 
Treatment of Immunocholangitis 
Chaptet' 8 
BUDESONIDE OR PREDNISONE IN COJl.IBINATION WITH 
URSODEOXYCHOLIC ACID IN PRIMARY SCLEROSING CHOLANGITIS: A 
RANDOMIZED DOUBLE· BLIND PILOT STUDY 
H.I.F. van Hoogstraten I, F.P. Vleggaar', OJ. Bolund2, \V. van Steenbergen3, P. Gtiffioen4, 
W.C.1. Hop5, 1. van Hattmn2, G.P. van Berge Henegouwen2, S.\\'. SchalmI and H.R. van 
Bumen l , representing the Belgian-Dutch PSC study group. 
Dept. of Gastroenterology and Hepatology, University Hospitals lRotterdam, 2Utrecht, 
3Leuven, The Netherlands & Belgium; 4Dept. of Clinical ChemistlY, 50ept. of Epidemiology 
and Biostatistics, University Hospital Rotterdam, The Netherlands. 
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Abstl'act 
PSC has characteristics of an (auto)immune-mediated disease; however, fe,\' studies 
have evaluated corticosteroid therapy for tlils disorder. \Ve performed an 8-week double-
blind randomized pilot study to assess the effects of additional treatment with 9 mg 
budesonide (11=6) versus 3 mg budesonide (n=6) versus 10 mg prednisone (n=6) in patients 
who had been treated with UDCA (mean dose 12 mg/kglday) for at least five months without 
achieving biochemical remission. Pruritus and fatigue were evaluated using visual analogue 
scales. ScmIll liver biochemistry was measured evclY four weeks. At cntry and at the end of 
the tliaI, adrenocorticotrophic hormone (ACTH) and dehydroepiandrosterone (DHEA) were 
measured to assess effects on the pituitru)'-adrcl1al axis. Duodenal bile was coHected for 
assessment of biliary corticosteroid activity. Pruritus decreased significantly more in the 
prednisone group compared to both the 3 mg and the 9 mg budesonide groups (p<0.05). 
Alkaline phosphatase (mean: -23.4%; p=0.03) and immunoglobulin G (mean: -16.2%; 
p=O.04) decreased in the prednisone group, while bilimbin, y-glutamyl transferasc, aspartate 
aminotransferase and alanine aminotransferase did not change significantly. No significant 
clinical and liver biochemical changes were observed in the 3 mg and 9 mg budesonide 
groups. Significantly larger drops in senUH ACTH were fOllnd in the 10 mg prednisone group 
(-40.7%; p=O.04) and 9 mg budesonide group (-36.6%; p=0.02) compared to the 3 mg 
budesonide group (+19.0%). No significant differences in percentage change in baseline 
values for DHEA between the three treatment anns were found. Mononuclear cell 
proliferation assays did not demonstrate c0I1icosteroid activity in bile. Auto-immune 
hepatitis was observed in onc case (9 mg budesollide) when corticosteroids were tapered off. 
The results of this pilot study suggest only minor beneficial short-tenn effects of prednisone 
but not budesonide on symptoms and serum liver tests in UDCA-treated PSC patients. 
Introduction 
The aetiology of primary sclerosing cholangitis (PSC) is unclear. An (auto)immune 
background is suggested (1, 2) by the strong association between PSC and inflammatory 
bowel disease (IBD) (3, 4), the presence of the autoantibody pANCA (5-8) and an increased 
prevalence of HLA B8 DR3 DR52a genotypes (9-11). FlIlihelmore, an overlap syndrome 
between autoimmune hepatitis (AllI) and PSC has been described (12-14). 
Few studies have evaluated the eiIeets of c011icosteroid treatment in PSC. Prednisone 
therapy has only been assessed in open-label studies (15, 16). The use of corticosteroids in 
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cholestatic liver disease has been discouraged because of potential side-effects. in particular 
osteoporosis (17). Systemic side-effects of corticosteroids may be avoided by replacing 
prednisone by budesonide, which is a potent corticosteroid with a high first-pass effect (18). 
resulting in low systemic availability and potentially fewer side-effects (19). 
Improvements in senUll liver function tests and histology have been observed following 
ursodeoxycholic acid (UDCA) Illonotherapy in PSC (20-22). Although effects on disease 
progression were absent after 2 years of treatment (23). the dmg is still being used 
extensively in PSC. In view of these facts. a double-blind randomized pilot study was 
initiated to evaluate the efficacy and safety of budesonide and prednisone in addition to 
UDCA maintenance therapy for PSC patients. 
Figure I. Study profile. 
Patients and methods 
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A total of 104 PSC patients was screened for eligibility; a 110w diagram according to the 
CONSORT statement (24) is given in Figure 1. Reasons for not participating are listed in 
Table I. Eighteen patients were recruited. The diagnosis of PSC was based on characteIistic 
findings on endoscopic retrograde cholangiography (ERC) (25) in 17 cases. Typical 
histological lesions (pcricholangiolar "onion-skin" fibrosis) (26) in combination with both a 
serum alkaline phosphatase (APh) level elevated to more than twice the upper limit of 
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nOlmal (ULN) and the presence of IBD led to the diagnosis of PSC in one patient. Prior to 
the study, all patients had been treated with UDCA (mean dose 12 mglkg body-weight/day) 
for at least five months, without achieving biochemical remission, defined as nonnalization 
of APh, aspartate aminotransferase (AST) and alanine aminotransferase (AL T). Exclusion 
criteria were: age >65 years, use of immunosuppressive dl1lgs such as c0l1icosteroids, 
azathioprine, cyclosporin or methotrexate, pregnancy, evidence of PSC-associated Am, 
previous cholecystectomy, presence of a biliary stellt and cirrhosis with a Child-Pugh score 
>6 (27). 
Patients were randomized by assigning consecutive treatment numbers which 
cOl1"esponded to trial medication. Patients were randomized to take 10 mg/day prednisone 
(two 5 mg tablets of prednisone and three placebo capsules Budenofalk®), 3 mg/day 
budesonide (one 3 mg Budenofalk® capsule, two placebo capsules and two placebo tablets 
of 5 mg prednisone) or 9 mg/day budesonide (three 3 mg Budenofalk® capsules and t\vo 
placebo tablets of 5 mg prednisone) for eight weeks. Venllll and placebo medication was of 
identical appearance. Treatment with UDCA was continued. Three blocks of six patients 
'vere generated. In each block, the three trcatmcnt options were equally and randomly 
distributed. One block of six treatment numbers was allocated to each pm1icipating centre: 
University Hospitals Rotterdam, Utrecht and Leuven. The randomization list was generated 
by Aliphamed, Goettingen, Germany; the medication was packed accordingly. Fol1ow~up 
data were collected every 4 weeks. Blood analysis including bilil11bin, APh, y-glutamyl 
transferase (y-GT), AST, ALT, immunoglobulin G (IgG), immunoglobulin M (IgM), 
albumin and prothrombin time was performed by standard automated procedures. Separation 
of APh isoenzymes was performed by agm-ose gel electrophoresis (Titan Gel®, Helena 
Laboratories, Gateshead, United Kingdom). Quantitation of APh isoenzyme fractions was 
performed by computerized scanning techniques (Sharp, JX330P). At baseline and after eight 
weeks, blood was drawn to assess adrenoc0l1icotrophic hormone (ACTH) and 
dehydroepiandrosterone (DHEA) after 30 minutes of bedrest, at 09.00 a.m., to detel111ine 
effects on the pituitary-adrenal axis. The severity of pruritus and fatigue was quantified with 
visual analogue scales (V AS), stru1ing one week before administration of the study 
medication. Patients were asked to indicate daily the severity of Pl1lritus and fatigue on a 10 
cm scale during the complete study period. After the 8-week study period all patients 
received treatment with 5 mg prednisone per day; subsequently, prednisone ,vas tapered off 
in three weeks. 
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Poor compliance was defined as taking less than 90% of the study medication. The study 
was approved by the Medical Ethics COlmmttees of each of the three pm1icipating hospitals 
and all patients gave written informed consent. All assessments, except the quantitation of 
APh isoenzymes, were pelfonned before the randomization code was broken. 
Collection of bUe and de/ennina/ioll of bilill1Y COlTIcostemid activity 
Bile was collected using duodenal intubation under fluoroscopic control at entry and on 
the last day of treatment. Gall-bladder contraction was induced by intravenous injection of 2 
~tg of cemletide (Takus®, Phannacia & Upjohn GmbH, Erlangcn, Germany). A maximum 
dose of 6 J.lg ceruletide was given in steps of 2 J.lg. Duodenal bile was collected in ice chilled 
tubes and stored at _20°C until further analysis. 
Mononuclear cells (l\1NCs) were isolated by Ficoll density centrifugation of heparinized 
blood from one healthy individual. 105 MNCs were incubated in RPMI culture medium 
supplemented with 10% AB-senlln in the presence of pre-treatment and post-treatment bile 
in a final dilution of 1:1000 (optimal dilution detennined in previous experiments). A 
mixture of diphtheria/tetanus toxoid was used for antigenic stimulation of MNC 
proliferation. To obtain reference values, prednisolone was added to the cultures in final 
dilutions of 10-4, 10-6 and 10"8 molll in the presence of bile collected at entry. Cultures 
without diphtheria/tetanus toxoid were used for detellllination of background MNC 
proliferation. MNCs were incubated at 37°C in 5% COl-atmosphere for five days; 3H_ 
thymidine was added 24 hours before harvesting. 3H-thymidine incorporation was measured 
with a liquid scintillation counter and MNC proliferation ,vas expressed as counts per minute 
(cpm). Phytohaemagglutinin was used to check the proliferative potential of the MNCs. 
Every culture was pelfonned in triplicate. 
Statistical analysis 
Since no data on the effects of budesonide and prednisone on liver biochemistty in 
PSC patients receiving UDCA were available and because this ,vas a pilot study, a 
statistical power analysis was not petfonned. A group of six patients per treatment arm was 
considered sufficient for this pilot study to get an impression of the efficacies. Data were 
analysed according to the intention-to-treat principle. Mean daily VAS scores per week for 
pruritus and fatigue were calculated by dividing the total score for one week by seven. 
Because the normal ranges for serum liver tests differed in the three participating centres, 
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results are expressed as multiples of the upper limit of normal (ULN). The K11lskal-\Vallis 
test was used to assess overall ditlerences between the three treatment arms. Paired t-tcsts 
were applied after verifying that differences between pre-treatment and post-treatment 
valucs exhibited an approximately normal disttibution; otherwise, \Vilcoxou's signed-rank 
test was used. A p-vaille ::;0.05 was considered statistically significant. 
Results 
At entry, the three groups were largely comparable in terms of clinical and biochemical 
characteristics (Table II). The mean age was 43 years (range 26-65); 14 patients were male 
and 11 (61%) had a histOlY of IBD. No significant differences in biochemical and clinical 
values at entry between the tlu'ce groups existed. Compliance was good; two patients used 
88% of the study medication, all others used 100% as indicated by pill count. 
PHllilus andjaligue 
Thc number of patients rep0l1ing pmritus at entty and after eight weeks was four and 
tlu'ee in the 10 mg prednisone group, two and none in the 3 mg budesonide group and one 
and two in the 9 mg budesonide group, rcspectively. The median difference between baseline 
and 8 weeks score was +0.15 points for the 3 mg budesollide group, -0.1 for the 9 mg 
budesonlde group and -1.1 for the 10 mg prednisone group. The median decrease from 
baseline in the 10 mg prednisone group was significantly greater compared to the other 
groups (both p<0.05) (Fig 2). 
Eleven paticnts complained of fatigue at entry: tlu'ec in the 10 mg prednisone group, 
thrce in the 3 mg budesonide group and five in the 9 mg budesonide group. After eight 
weeks, eight patients complained of fatigue: t,vo in the 10 mg prednisone group, three in the 
3 mg blldesonide group and three in the 9 mg budesonide group. The median change fmm 
baseline of the fatigue score was similar in all groups (all 0.6) (Fig 3). 
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Figure 2. The difference between pre-treatment and 8-week VAS pruritus score in 3 mg 
budesonide (bud 3 mg), 9 mg budesonidc (bud 9 mg) and 10 mg prednisone (pred 10 mg) groups. 
Horizontal bars indicate medians. 
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Figure 3. The difference between pre-treatment and 8-week VAS fatigue score in 3 mg budesonidc 
(bud 3 rug), 9 mg budesonide (bud 9 mg) and 10 mg prednisone (pred to mg) groups, 
Horizontal bars indicate medians. 
Sel1lf11 Iiverlesfs 
In the 10 mg prednisone group, the mean changes from baseline in APh (-23.4%. 
p=O_03; 95%-confidence interval: -42_7% to -4.2%) (Fig 4) and IgO (-16.2%, p=O.04; 95%-
ci: -24.8% to -7.5%) ,,,ere significantly less than zero after eight weeks of treatment. The 
liver and bone APh isoenzyme fractions decreased by a mean of 27.6% (95%-ci: -54.5% to -
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0.8%; p~0.04) and 10.0% (95%-ci: -38.1 % to + 18.0%; p~0.9), respectively. No significant 
changes in Senlll1 liver tests were observed in the 3 mg budesonide and 9 mg budesonide 
groups. The mean changes in APh and IgG in the 10 mg prednisone group, hmvever, did not 
differ significantly from the changes in the 3 rug and 9 mg budesonide groups. Senlll1 
bilil1lbin (Fig 5), AST, ALT, rOT and IgM did not change significantly in the 10 mg 
prednisone group. Albumin and prothrombin time remained stable in all three groups. 
p=O.03 
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Figure 4. Course of serum alkaline phosphatase in the 10 mg prednisone, 9 mg budcsonide 
and 3 rug budesonide groups. Data are expressed as multiples of the upper limit of normal 
(ULN), Horizontal bars indicate medians. 
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Figure 5. Course of serum bilirubin in the lO mg prednisone, 9 rug budesonide 
and 3 mg budesonide groups. Data are expressed as mUltiples of the upper limit of Ilonnal 
(ULN). Horizontal bars indicate medians. 
Pitllifw),-adrenol m"is 
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Significantly greater decreases in serum ACTH ,vere found in the 10 mg prednisone 
group (-40.7%; p=0.04) and 9 mg budesonide group (-36.6%; p=0.02) compared to the 3 mg 
budesonide group (+19.0%)(Table III). No significant differences in percentage change in 
baseline values for DHEA between the three treatment anns were found. 
Adverse events 
A 42-year-old male patient was diagnosed with PSC in 1991. At regular follow-up 
examinations transaminases were mildly elevated and IgG was nonnaI. He was allocated to 
the 9 mg budesonide group; he had also taken Iifampicin for pruritus in the preceding 6 
months. \Vhen prednisone was tapered off marked hepatitis developed: serum bilirubin 105 
frmoVI (nOlmal <17 funoVI); ALT 595 VII (nonnal <30); IgG 23.2 gil (nOl111al <16). 
Antinuclear antibodies (titre 1:2560), anti-DNA (>50 !Elml), anti SS-A and anti SS-B 
antibodies tested positive. Serological markers for hepatitis A, Band C were negative. A 
liver biopsy revealed dense pOltal mononuclear infiltrates with interface hepatitis, numerous 
Councilman bodies and collapse of liver parenchyma. Combination treatment with 
prednisone (30 mglday) and azathioprine (50 mglday) was instituted, resulting in rapid 
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nOllnalization of sennll bilirubin, ALT and IgG. An overlap syndrome of PSC and AIH ,vas 
diagnosed. 
One patient, who received 10 mg prednisone per day reported slightly impaired vision 
and itching of the eyes. In the 9 mg budesonide group, one patient repOlted increased facial 
acne and another patient complained of nausea. These side-effects were found to be transient. 
No other adverse events were noted. 
Bilitll)' cOIticosleroid activity 
Duodenal bile collection was successful in 15 cases; it failed in two patients of the 9 mg 
budesonide group and one patient of thc 3 mg budesonlde group. Mean cpm of 
diphthetialtetanus toxoid-stimulated MNCs incubated with bile collected at entry with and 
without il/vitlV addition of 10-8 molll prednisolone was 11504.0 (sd 6235.1) and 15614.6 (sd 
6188.1), respectively (p=O.OI). Thus, it was possible to measure an inhibitory effect 
comparable to that of prednisolone at a concentration of 10's molJl, conesponding to a 
concentration of 10,5 moVI in undiluted bilc. Mean CPIll of diphtheria/tetanus toxoid-
stimulated MNCs incubated with bile collected at entry and at the end of the study was 
15614.6 (sd 6188.1) and 15073.9 (sd 8586.3), respectively (p=0.36). In none of the groups 
could an inhibitory effect of post-treatment bile compared with pre-treatment bile on NINC 
proliferation be demonstrated. 
DisclIssion 
Tilis study indicates that in PSC patients receiving treatment with ursodeoxycholic acid 
additional therapy with 10 mg prednisone per day or 3 or 9 mg budesonide per day does not 
result in major shOlt-term improvements in clinical and laboratory parameters of the disease, 
although treatment with 10 mg prednisone per day was associated with a significant decrease 
in Pl1lritus as assessed by visual analogue scores. 
Currently, no effective medical treatment has been found for PSC. This study was based 
on the hypothesis that both inullullologically mediated inflammatory activity (1) as well as 
bile acid-related liver damage contribute to the gradually progressive liver disease that 
characterizes PSC. Consequently, a therapeutic approach based on combined treatment with 
ursodeoxycholic acid and low-dose llnmunosuppressives was considered of interest. 
\Ve chose deliberately for a relatively shott pilot trial considering the virtual lack of data 
indicating a beneficial effect of cOlticosteroids ill PSC and the potential significant side-
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effects of these agents. Therefore, the results of tIlis 8-week study do not allow conclusions 
as to the possible long-tellll effects of such treatment regimen but they do seem to indicate an 
absence of major shorHerm benefits. The results of this 8-week study do not allmv 
conclusions as to the possible long-term effects of such a treatment regimen but they do seem 
to indicate an absence of major shOlt-term benefits. In this context, it should be noted that the 
patients included in this study had relatively mild liver disease, as indicated by the 
biochemical test results at entry, which maya priori have limited the chance to observe 
significant changes in liver biochemical parameters upon treatment with 
imlllunosuppressives. On the other hand, ill two other chronic autoimmune liver disorders, 
primary biliary cinhosis (28) and autoitmnune hepatitis (29), a biochemical response to 
corticosteroid therapy was already apparent after only four weeks of treatment. 
Interpretation of the effect of c0l1icosteroids on pnllitus is markedly hampered by the 
considerable variation in both the number of symptomatic patients and the sevetity of 
pruritus among the treatment groups .. Moreover, this study was not placebo-controlled. 
Therefore, the observed beneficial effect of prednisone should be interpreted with caution 
and would require confll'lnation in further studies. Interestingly, a positive effect of 
c0I1icosteroids on pruritus has also been repOited for another cholestatic liver disease, 
primmy biliary cirrhosis (28, 30). This effect could be related to the reported ability of 
c0l1icosteroids to induce cytochrome P450-3A activity (31), wllich is analogous to the action 
of the well-known antipruritic dl11g rifampicin. 
Budesonide is a potent cOlticosteroid with high receptor affInity. It is rapidly 
metabolized in the liver into almost inactive metabolites (32). In theory, a lligh concentration 
of active drug could be delivered to the biliary tract, whereas systenlic concentrations remain 
low. On the other hand, budesonide might be inactivated before exerting its 
immunosuppressive effect. The flrst hypothesis is not supported by the results of our 
experiments with duodenal bile, showing absence of increased immunosuppressive action in 
bile of patients treated with budesonide. 
This study demonstrates that suppression of the pituitary-adrenal axis by 10 mg 
prednisone per day and 9 mg budesonide per day ,vas comparable wllile 3 mg blldesonide per 
day had no such effect. Although the systemic availability of buclesonide is reported to be 
low (32,33) we, in accordance with others (19, 34), found that in patients treated with 9 mg 
budesonide as well as 10 mg prednisone the pituitary-adrenal axis was significantly 
suppressed. 
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In general, patients tolerated the low-dose c0l1icosteroid regimen well. One exceptional 
serious adverse event was observed in a patient treated with 9 mg budesonide per day who 
developed severe, corticosteroid-responsive hepatitis when c0l1icosteroids were tapered off. 
We are not aware of any similar cases. Although the aetiopathogenesis of this event remains 
speculative, available data suggest that in tlus patient mmupulation of the immune system 
triggered the development of an autoimmune-mediated liver disease. 
Relatively few studies have evaluated the effects of immunosuppressive drugs in PSC and 
the findings are inconsistent. No evidence was found for beneficial effects of D-
penicillamine (35), cyclosporin (36), methotrexate (37, 38) or combination therapy with 
colchicine and prednisone (16). Conversely, serum liver tests appeared to respond favourably 
to treatment with tacrolimus (39) whereas some benefit of treatment with prednisone 
monotherapy has been repOJ1ed for a series of ten patients (15). 
In conclusion, in this pilot study only minor sh0l1-tenn beneficial effects of treatment 
with prednisone but not budesonide were noted in PSc. The apparent benefit-risk ratio of 
immunomodulating agents, as assessed in this and previous studies, does not therefore 
support long-term evaluation of these agents in PSC. 
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Table 1. Reasons for not randomizing a patient. 
patient refused 
use of immunosuppressive medication 
biochemical remission 
no UDCA treatment 
previous cholecystectomy 
biliary stent 
Child-Pugh score >6 
presence of malignancy/other severe disease 
PSC associated AIH 
age >65 years 
AIH: autoimmune hepatitis. 
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13 
13 
33 
8 
4 
2 
3 
6 
3 
Table ll. Features at entry. 
Prednisone 10 mg Budesonide 9 mg 
n::::6 11::::6 
Age (years) 44.5 (l0.9) 4604 (9.7) 
Sex (male/female) M6/FO M4/F2 
UDCA dose (mg/kg) 11.8 (2.2) lOA (2.2) 
lED (11) 3 UC/I CD 2UC/ICD 
Treatment with 
5-ASA (11) 4 3 
Ril~1mpicin (n) 0 
Bilimbin (ULN) l.l (0.3) 0.9 (004) 
APh (ULN) 204 (0.9) 1.8 (104) 
y-GT(ULN) 6.5 (5.0) 6.4 (7.9) 
AST(ULN) 1.2 (0.4) 1.2 (1.0) 
ALT(ULN) 2.0 (0.9) 1.7 (2.2) 
Albllmin (ULN) 1.0 (0.3) 1.0 (0.3) 
IgG(ULN) 1.2 (0.7) 0.9 (0.3) 
Means with standard deviation in parentheses. mD: inflammatory bowel disease; 
UC: ulcerative colitis; CD: Crohn's disease; 5-ASA: 5-amino salicylic acid 
III 
Budesonide 3 mg 
11::::6 
38.9 (l2.3) 
M4/F2 
14.6 (6.8) 
4 UC/OCD 
3 
0 
0.8 (0.3) 
2.8 (lA) 
7.8 (6.6) 
1.3 (004) 
1.9 (0.6) 
1.0 (0.2) 
1.0 (0.3) 
Table 111. Etfects of prednisone and budesonide on the pituitaIy-adrenal axis. 
Entry End tI 
, 
P 
ACTH (pg/l) 
Prednisone 10 mg 4S.0 (14.6) 27.5 (21.9) -40.7 (23.0) 0.130 
Budesonide 9 mg 35.S (7.3) 21.7 (9.1) -36.6 (1304) 0.064 
Budesonide 3 mg 3S.1 (1304) 44.0 (14.5) +19.0 (13.6) 0.219 
DHEA (flinolll) 
Prednisone 10 mg 504 (2.S) 2.6 (1.0) -39.2 (I5.9) O.OSI 
Budesonide 9 mg 5.8 (3.3) 3.7 (3.1) -40.9 (lOA) 0.052 
Budesollide 3 mg 3.7(1.5) 3.5 (104) -7.1 (SA) 0.359 
Means with standard deviation in parentheses. A: percentage change from baseline with 
standard elTOl" of the mean in parentheses. 
* within group comparison. 
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Chaple.· 9 
SCLEROSING PANCREATO·CHOLANGITIS RESPONSIVE TO STEROID 
THERAPY 
G.\V. Erkelens i , P.P. Vleggaar2, \V. Lesterhuis3 , H.R. van BUUfcn2, S.D.1. van derWerfl 
IDepartment of Internal Medicine and Gastroenterology. \Vesteinde Hospital, The Hague, 
The netherlands; 2Departmcllt of Gastroenterology and Hepatology. University Hospital 
Rotterdam, The Netherlands; 3Department of Intcmal Medicine, Albert Schweitzer Hospital, 
Dordrecht, The netherlands. 
Lallcet 1999; 354: 43·44. 
Multiple fibrosing inflammatory strictures of the biliary tree can be caused by primary 
sclerosing cholangitis (PSC) or may be secondary to a number of other diseases. In both 
primary and secondary sclerosing cholangitis success of medical treatment has been 
limited. Reversibility of biliary abnormalities upon treatment with immunosuppressives 
has not been documented. \Ve report on multifocal bile duct stenoses responding to 
gll1cocorticosteroids in four patients with a rare inflammatory disorder involving the 
pancreato-biliary tract. 
Four male patients (aged 19, 51, 61, 63 years) with an unremarkable medical history 
presented with weight loss (6-12 kg) and jaundice. The most pertinent laboratOl), results 
were: elevated ESR (55-89 nun/h); hyperbilimbinaemia (n=3; bilirubin 47-150 fnnol/I); 
elevated alkaline phosphatase (307-539 V/I; N<l20), decreased faecal elastase-I levels 
(tested in three patients) indicating severe exocrine pancreatic insufficiency and previously 
unknown hyperglycaemia (n=1). Ultrasound and CT studies showed diffuse (11=2) or focal 
(n=2) pancreatic enlargement. Endoscopic retrograde cholangiopallcreatography (n=3) and 
percutaneous transhepatic cholangiography (n= 1) demonstrated multiple strictures of the 
intrahepatic bile ducts (n=4), distal stenoses of the common bile duct (n=2) and llaITowing 
and irregularity of the main pancreatic duct (n=3). Liver biopsy specimens revealed 
periductal inflammation and fibrosis (n=4). During diagnostic laparotomy, pelfonned in two 
cases, diffuse sw€iling of the entire pancreas without features of malignancy was noted. A 
pancreatic biopsy from olle patient showed fibrosis and extensive inflammatory infiltrates; 
malignancy was not found. 111ere were no clinical symptoms of inflammatory bmvel disease 
and colonoscopy, caITied out in three cases, was nOlmal. 
For all 4 patients, the diagnosis was pancreatitis ussociated with 'PSC-like' bile duct 
abnormalities on a presumably autoimmune basis and therapy with prednisone (0.5-1.0 
mglkg/day, tapered to a maintenance dose of 5-10 mglday) was instituted. One patient also 
took 50 mg azathioprine daily and two patients received bilimy endoprostheses tempofalily. 
In all cases, complete clinical remission was observed, as confinned by normalization of 
biochemical liver function tests, improvement in liver histology (11=2) and ultrasound studies 
indicating disappearance of pancreatic swelling. The patient \vith diabetes mellitus became 
nortnoglycaemic. Repeat cholangiography showed complete disappearance of bile duct 
stenoses after three months in one patient (figure lA+B) and marked improvements in biliary 
abnormalities after two years in the other three patients. 
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The peculiar type of pancreatic disease in our patients is quite different from pancreatic 
abnormalities that have been repOJ1ed previously in PSC I . Furthennore, the absence of 
inflammatOl), bowel disease and the favourable response to c0l1icosteroids plead against this 
diagnosis. Four similar patients with a favourable response to corticosteroid treatment have 
been descdbed2-5 but effects on radiological bile duct abnormalities were not assessed. Our 
patients seem to fit within an entity that has been rep0l1ed under the name of 
'lymphoplasmacytic sclerosing pancreatitis with cholangitis', 'pancreatic pseudotllmor \vith 
idiopathic fibrosc1erosis', 'inflammatOl)' pseudotllmor from sclerosing cholangitis'. and 
others. 
Awareness of this intdguing syndrome may prevent confusion with pancreatic malignan-
cy and unnecessary surgery. Until the aetiopathogenesis and natural history have been 
defined more precisely. no clear recommendations with respect to medical therapy can be 
made. However. our observations as well as those of others at least suggest that 
c0l1icosteroids should be considered for patients who apparently seem to suffer from 
'sclerosing pancreato-cholangitis'. 
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Figure lA. Pre-treatment endoscopic retrograde cholangiography (ERC) showing stenosis 
of the intrapancreatic part of the common bile duct (CaD) and multiple centrally located 
Figure lB. ERC after three months of prednisone and azathioprine therapy showing 
disappearance of the CBO stenosis as well as the intrahepatic bile duct strictures. 
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Abstract 
Smoking is associated with a decreased risk of primary sclerosing cholangitis. \Ve aimed to 
explore the therapeutic efficacy of and tolerance for transdermal nicotine treatment in this 
disease. Twelve patients (11 males; 37±6 years; 6 with ulcerative colitis) who did not achieve 
complete biochemical remission on ursodeoxycholic acid (14 mg/kg/day) were treated in a 
randomized cross-over trial with transdennal nicotine (15 mg/day) or a placebo, each for eight 
weeks (4-week washout period between treatments). One patient developed de novo ulcerative 
colitis and two did not complete the entire protocol because of intercurrent bacterial 
cholangitis. Baseline values (mean + range) were: bilimbin 1.3 (0.5-2.6), APh 2.5 (1.4-4.7), 
yGT 7.7 (0.7-38), AST 1.9 (0.5-3.2), ALT 2.4 (0.4-7.3) and bile salts and 10.9 (2.1-39) times 
the upper limit of normal. No significant effect on pruritus or fatigue was noted during either 
period, but a small increase in bodyweight was observed during placebo treatment. No 
significant differences were observed between the two treatment modalities after 8 weeks in 
bilimbin (nicotine vs placebo: +13% vs -6% change fi·om baseline), API! (-3% vs -17%), yGT 
(-11% vs -13%), AST (+2% vs -10%), ALT (-1% vs -11%) or bile salts (+36% vs -3%). 
Transdermal nicotine does not seem to have a clear short-term beneficial effect ill primary 
sclerosing cholangitis treated with ursodeoxycholic acid. 
Introduction 
Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease characterized 
by multifocal strictures of intrahepatic and extrahepatic bile ducts, which frequently leads to 
biliary cirrhosis and liver failure (1). Approximately 70% of patients with PSC have associated 
inflammatory bowel disease, usually ulcerative colitis (2). Conversely, 2 to 7% of those with 
ulcerative colitis have concomitant PSC (3, 4). The aetiology of PSC is unknown but is thought 
to be (auto)illlmulle-mediated. Nevertheless, in a number of randomized controlled trials a clear 
benefit of treatment with various immunosuppressive agents, such as D-penicil1amine (5), 
methotrexate (6) or corticosteroids (7), could not be demonstrated. Although treatment with 
ursodeoxycholic acid (UDCA) improves serum liver tests (8, 9) and is prescribed on a large 
scale for PSC patients, this therapeutic modality may have no beneficial effect on the course of 
the disease (10). 
Smoking of cigarettes is associated with a decreased risk of ulcerative colitis (11). Treatment 
with transdermal nicotine patches may improve symptoms and histology in active ulcerative 
colitis (12, 13), supposedly by influencing the synthesis of various cytokines (14). Three case-
control studies have demonstrated that cigarette smoking is also associated with a decreased risk 
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of PSC (15-17). These findings suggest that transdennal nicotine might have a benelicial effect 
in PSC. \Ve therefore performed a placebo-controlled cross-over study to explore safety and 
efficacy of transdermal nicotine treatment in PSC. 
Patients and methods 
Exclusion criteria for the study were: smoking \vithin three months prior to cntry. use of 
immunosuppressive drugs such as corticosteroids, azathioprine, cyclosporln or methotrexate in 
the previous six months, active ulcerative colitis (18), Crohn's disease, pregnancy, presence of a 
biliary endoprosthesis, evidence of PSC-associated autoimmune hepatitis and cirrhosis with a 
Child-Pugh score >6 points (19). The diagnosis of PSC was based on characteristic findings on 
endoscopic retrograde cholangiography (20), Prior to the study, all patients had been treated with 
UDCA (mean dose 14 mg/kg bodyweight/day) for at least six months, without normalization of 
alkaline phosphatase (APh), aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT). 
Patients were randomized to receive the transdennal nicotine patch or an identical placebo 
patch (Nicorette®, Pharmacia & Upjohn AB, Stockholm, Sweden) for eight weeks. After a 
wash-out peliod of four weeks, cross-over to the opposite treatment for another eight \veeks 
followed. The starting nicotine dose was 5 mg/day. The dose \vas increased by 5 mg every three 
days until a maintenance dose of 15 mg daily was achieved. The nicotine or placebo patches 
were applied from 7:00 a.m. until 23:00 p.m .. Treatment with UDCA was continued in the same 
dose as before. 
Follow-up data were collected at 4-week intervals. Blood analysis performed on these 
occasions included: bilimbin, APh, y-glutamyl transpeptidase (y-GT), AST, ALT, lactate 
dehydrogenase (LD), total cholesterol, total bile salts, albumin, prothrombin time (PT), 
immunoglobulin G (IgG), erythrocyte sedimentation rate (ESR) and haematological indices 
(haemoglobin level, leucocyte and thrombocyte counts). Systolic and diastolic blood pressures, 
heal1 rate and bodyweight were also measured. Severity of pmritus and t~1tigue were quantified 
at baseline and during both treatment periods: patients were asked to indicate severity of pmritus 
and fatigue on 10 em visual analogue scales (V AS) every night at bedtime during the study 
period. 
The study was approved by the Medical Ethics Committees of the two participating hospitals 
and all patients gave written infonned consent. 
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Statistical analysis 
Since no data on the effects of transdennal nicotine on serum liver tests in PSC patients 
during UDCA maintenance therapy were available, a formal statistical pO\ver analysis was not 
performed. T\velve patients, treated according to a cross-over study design, were considered 
sufficient to get an impression of the potential efficacy of nicotine. Data were analysed 
according to the intent-to-treat principle; of one patient, who dropped out after 4 weeks of 
treatment in the second period, the last-observation-carried-forward method was used to obtain 
an 8-weeks outcome. A per-protocol analysis was also performed. Mean daily visual analogue 
scores for pruritus and fatigue for each week were calculated by dividing the total week score by 
seven. Serum liver tests were expressed as multiples of the upper limit of normal (xULN). 
Statistical analysis of these parameters was performed after logmithmic transformation to obtain 
approximately normal distribution. The absence of possible carry-over and period effects was 
assessed using methods appropriate for cross-over studies (21). Paired t-tests were used to 
compare the effects of both treatments. In a single instance, \Vi1coxon's signed-rank test was 
used. A two-sided p-value ..s;0.05 was considered statistically significant. 
Results 
Twelve patients with PSC (II males) were included in the study. The median age was 37 
(range 29-50) years. SL'{ patients suffered from ulcerative colitis which was clinically in 
remission in all cases. Both intra- and extrahepatic bile ducts were affected in all cases. Other 
baseline patient characteristics are listed in Table I. 
Adverse e\'el1ts and droP-Olits 
One patient with increasing ESR and thrombocyte counts and decreasing haemoglobin during 
the trial period appeared to have developed severe de novo ulcerative colitis, according to 
colonoscopic evaluation performed after the study_ Two patients dropped out of the study after 
the first period because of cholangitis necessitating endoscopic stent placement: one in the wash-
out period following placebo, the other in the second period after 4 weeks of nicotine treatment. 
The nicotine dosage had to be reduced to 7.5 mg per day in two cases because of nausea, 
vomiting and dizziness which occurred within one week of treatment. 
Symptoms alld physical examination 
No statistically significant changes in pruritus or fatigue were observed during either period. 
Mean change in bod}weight was +1.0 (SD 1.0) kilogram and +0.1 (SD 1.4) kilogram during 
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placebo and nicotine treatment, respectively (p=O.04). No significant changes in heart rate or 
blood pressures were found during the placebo or nicotine treatment periods. 
Se17lm liver tests 
Mean changes in serum Hver tests during nicotine treatment did not differ significantly from 
those during placebo treatment (Table II). Subgroup analysis for patients with and without 
ulcerative colitis yielded the same conclusion. Ovcral1, semm markcrs for cholestasis (in 
particular APh; Fig 1) and hepatitis tended to decrcase more during the placebo period than 
during the nicotine period, but significance was not reached. Haematological indices remained 
stable during both treatment pcriods. Separate analysis without the patients \vho did not 
complete the entire study protocol gave essentially thc same results. 
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Figure 1. Course of serum alkaline phosphatase (APb) in PSC patients during eight weeks of nicotine and placebo 
treatment. Data arc expressed as multiples of the upper limit of normal (ULN). Horizontal bars indicate means. 
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Discussion 
In this study, we found no evidence of a beneficial effect of short-term transdermal nicotine 
administration on symptoms and serum liver tests for PSC patients on UDCA maintenance 
therapy. Previous uncontrolled observations of the oral administration of nicotine to PSC 
patients (22) are in agreement with the results of this study. 
The reasons for this study were the previously reported association of PSC with nonsmoking 
(15-17) and the positive effects of transdennal nicotine treatment on u1cerative colitis (12, 13), 
which exhibits a similar association \vith nonsmoking (11). \Ve 
chose to continue treatment of our patients with UDCA because a synergistic effect of 
hydrophilic bile salts and additional immunomodulating therapies might positively influence 
liver biochemistry and the course of PSc. \Ve therefore cannot exclude the possibility that liver 
biochemistry improves in patients who do not receive UDCA. 
Another possible explanation for the absence of significant effects on liver biochemistry lllay 
be that the amounts of nicotine administered in this study were relatively low. In ulcerative 
colitis, it has been suggested that a nicotine dose of 20-25 mg/day is more effective than a dose 
of 15 mg/day (13), as used in the present study. However we also took into account the fact that 
high nicotine dosages are associated with a high incidence of side-effects and marked drop·out 
rates (12, 13). Our patients tolerated a dose of 15 mg/day reasonably well. The somewhat 
unexpected finding of a slight but statistically significant increase in bodyweight in the placebo 
period compared to the nicotine period may be explained by the well-known ability of nicotine 
to suppress appetite (23, 24), This effect, however, cannot be considered positive for patients 
with a chronic cholestatic liver disease. 
A third explanation may be that the apparent association between PSC and nonsmoking (15-
17) is biased by concomitant ulcerative colitis (25). The development of ulcerative colitis in one 
of our trial patients, who had had two normal coionoscopic examinations in the past 10 years, 
underlines the difficulty of assessing the true prevalence of ulcerative colitis in PSC. 
A further explanation for the absence of apparent beneficial effects of nicotine may be that 
the drug decreases the risk of developing PSC but does not change the course of stablished 
disease. All of our patients had extensive intrahepatic and extrahepatic bile duct abnonnalities 
when they were included in the study. 
Finally, both the relatively small number of patients studied and the duration of treatment 
may explain why we \vere unable to detect a positive effect of nicotine. 
When we calculated the 95% confidence interval for the difference (nicotine minus placebo) 
of the percentage decrease from baseline of APh, \ve found this interval to range from -1 % up to 
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34%. Although this range is obviously wide, it also shmvs that the advantage of nicotine is at 
1110st a 1 % greater decrease as compared to placebo. Such a decrease is clinically irrelevant. 
There were several reasons for choosing a treatment period of two months. The main reason 
was that, in the absence of data with respect to potential benefits, safety and tolerance, it was 
considered ethically difficult to recruit patients for a blinded trial of longer duration. The 
possibility was realized that bencficial treatment effects could only become apparent after more 
prolonged treatment. However, this was considered unlikely consideting the reported experience 
with nicotine in ulcerative colitis. We also believe that a dmg that has no positive short-term 
effects on biochemical liver tests andlor symptoms is unlikely to have significant therapeutic 
potential when administered for longer time. Moreover, to establish whether a treatment 
influences the natural course of slowly progressive disorders such as PSC requires large 
populations treated and followed for many, at least 3-5, years. Such studies are only justified and 
feasible when sufficient evidence for a potentiallong-tenn treatment eHect has been established. 
Therefore, this study ,vas primarily intended as a pilot investigation, to explore the potential 
efficacy and tolerance of a new treatment option. 
A substantial number of medical therapies has been evaluated in controlled trials with PSC 
patients. The first reports on the effects of treatmcnt with UDCA on scrum liver tests were 
promising (8, 26, 27), but long-term effects on clinical diseasc progression have been 
disappointing so far (10). No clear-cut bencficial cffects were found for monothcrapy with D-
pcnicillamine (5), methotrexate (6), or a combination of UDCA with budesonidc, prednisone (7) 
or methotrexate (28). Although, the present study does not defInitively exclude a benefIcial 
effect of nicotine treatment for PSC patients, the results indicate that such effect is not likely. 
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Table I. Baseline characteristics of 12 patients with primary sclerosing cholangitis. 
age (years) 37.1 ± 6.3 
Sex (male !female) IIII 
intra-/ extrahepatic PSC / combined 
UDCA dose (mg I kg I day) 
ulcerative colitis (n) 
5-amino salicylic acid (n) 
bilirubin (xULN) 
APh (xULN) 
yGT (xULN) 
AST(xULN) 
ALT (xULN) 
LD (xULN) 
total cholesterol (xULN) 
total bile salts (xULN) 
albumin (xULN) 
PT (xULN) 
IgG (xULN) 
0/0/12 
13.5 ± 4.1 
6 (50%) 
6 (50%) 
1.3 (0.5·2.6) 
2.5 (1.4·4.7) 
7.7 (0.7-38.0) 
1.9 (0.5-3.2) 
2.4 (0.4-7.3) 
0.7 (0.5-1.2) 
0.9 (0.6·1.4) 
10.9 (2.1-39.0) 
0.8 (0.7-0.9) 
0.9 (0.7-1.1) 
1.2 (0.8·1.7) 
Means \vith ranges in parentheses. xULN: multiples of the upper limit of normal. 
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Table ll. Mean percentage changes from baseline (95% confidence intervals in parentheses) of serum liver tests during nicotine and placebo 
treaUTIent. 
Nicotine placebo p-value • 
o vs 4 weeks o vs 8 weeks o vs4weeks o vs 8 weeks o vs4 Ovs 8 
weeks weeks 
Bilirubin +11 (-18, +50) +13 (-16,+52) +2 (-11.+17) -6 (-16, +5) 0.61 0.22 
Aph -4 (-19, +14) -3 (-18, +14) -12 (-21. -1) -17 (-22, -11) 0.21 0.06 
y-GT -5 (-19, +11) -11 (-20,0) -10 (-21. +3) -13 (-22, -3) 0,42 0.62 
AST + I (-29, +43) +2 (-24, +37) -6 (-18, +7) -10 (-24, +7) 0.65 0.33 
ALT 0(-31. +47) -I (-29, +39) -9 (-28, +14) -11 (-28, +12) 0.50 0,49 
LD -7 (-20,+7) -11 (-33, +17) +6 (-6, +18) +4 (-5,+15) 0.l7 0.25 
Cholesterol -2 (-10, +7) -4(-12+6) 0(-7,+7) -2 (-9, +6) 0.83 0.77 
Bile salts +13 (-32, +87) +36 (-12, +110) +37 (-20, +136) -3 (-38, +52) 0.53 0.30 
Albumin -1 (-6,+3) -5 (-15, +7) -2(-6,+1) -3 (-7, +2) 0.76 0.70 
PT -I (-4, +3) -I (-5, +3) -I (-7, +6) 0(-7, +8) 0,98 0.68 
IgG -I (-6, +4) +4 (-4, +13) +2(-1.+5) +2 (-3,- +6) 0.38 0.63 
, 
p-value for the comparison of the %-changes from baseline during nicotine and placebo treaUTIent 
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Summary 
Primary sclerosing cholangitis (PSC) and primary biliary cilThosis (PBC), collectively 
also called immunocholangitis, are not well-defined liver diseases. Both terms represent a 
wide range of disorders whereby some characteristics may be indicative of one of the 
diseases in the restricted sense. 
Demonstration of antimitochondrial antibodies and non-suppurative destmctive 
cholangitis in patients with cholestatic serum Jiver tests justifies the diagnosis of PBC. 
However diagnostic evaluation should not be stopped at tiils point and concomitant liver-
related signs and symptoms should not be disregarded. When severe (icteric) hepatitis with 
hypcrgall1l11aglobulinaemia OCClJrs in a PBe patient, the possibility of a PBC-autoinullune 
hepatitis (AIH) overlap syndrome should be considered. Cholestatic jaundice, often 
accompanied by refractory pruritus and weight loss, in a non-cirrhotic PBC patient with 
normal liver synthesis capacity may be indicative of premature ductopenic PBe. These 
variants of ordinalY PBC can be seen as the extremes of the PBC spectrum. In the PBC-
AIH overlap syndrome, inflammation of (lobular) liver parenchyma determines the 
cwilcal, biochemical and histological patterns. In contrast, severe interlobular bile duct 
loss dictates the clinical, biochemical and histological patterns of the premature ductopenic 
vm'iant of PBC. 
When cholangiography shows multiple bilialY strictures and dilatations, PSC should 
not be diagnosed automatically since the biliary system possesses a rather limited 
repertoire of responses to a large variety of local and systemic pathological processes. 
Identical cholangiographical pictures can be encountered in 'sclerosing pancreato-
cholangitis' and PSe. Sclerosing pancreato-cholangitis is distinguished from PSC in the 
narrow sense by its occurrence in nilddle-aged men, the absence of concomitant 
inflammatory bowel disease and an initial presentation mimicking that of pancreatic 
cancer. Furthermore, in addition to systemic disorders such as AIDS, 'graft-versus-host' 
disease and systemic idiopathic fibrosis, local abnonnalities such as pOlial vein thrombosis 
follmved by cavernomatous transformation may also cause sclerosing cholangitis. As in 
PBC, AIH can also coincide with PSC. The PSC-Alli overlap syndrome seems to occur in 
approximately 10% of a PSC patient population, thereby suggesting a higher prevalence 
than was previously presumed. 
Tlils further differentiation of sclerosing cholangitis and primary biliary cirrhosis is not 
only scientifically interesting from the standpoint of classification, but also has clear value 
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for clinical decision-making with respect to prognosis and treatment of the individual 
patient. The abnormalities of sclerosing pancreato-cholangitis respond quite well to 
therapy with prednisone, whereas PSC does not seem to benefit from this approach. Other 
phannaseuticai options, such as nicotine and budesol1ide, also do not have a positive 
influence on PSC. In case of an overlap of PSC or PBC with AnI immunosuppressive 
therapy with prednisone and possibly also azathioprine should be instituted. The AIH-
component in particular can be suppressed effectively in these disorders. In contrast to 
ordinary PBC the premature ductopenic variant does not seem to benefit from trcatment 
with ursodeoxycholic acid and immullosuppressives. Consideration of early liver 
transplantation for treatment of refactOlY pmrihls and prevention of ongoing weight loss 
seems indicated for this category of patients. 
In addition to the establishment of a diagnosis that describes the disorder of the 
individual patient, a reliable estimation of the prognosis of that disease is an important 
aspect of the management of a patient with immul1ocholangitis. The mathematical 
prognostic models developed by the Mayo Clinics merely facilitate the timing of liver 
transplantation, since the entry variables of these models depend on the severity of the liver 
disease itself. Several factors which are independent of the stage of PBC, such as AMA-
profiles and AMA-titres, unfortunately have hlrned out to be unable to differentiate 
between a progressive and 11 relatively benign course of disease. In PSC, a prognostic 
factor which is independent of the stage of disease is also unknown. However, the 
occurrence of PSC-specific complications, such as a dominant bile duct stricture, 
suppurative cholangitis or cholangiocarcinoma, during the course of disease appears to be 
associated with a shorter transplantation-free survival. 
An increase in our knowledge of these diseases will hopefully enable us to determine 
the prognosis for the individual inul1ullocholangitis patient in order to institute tailor-made 
treatment in the future. 
Samenvatting 
Primaire scleroserende cholangitis (PSC) en primaire biliaire cirrose (PBC), tezamen 
ook wei immuuncholangitis genocmd, zijn niet twee duidelijk afgebakcnde leverziekten. 
Beide vertegenwoordigen spectra van aandoeningen waarV3n sOll1mige kemnerkcn cen 
indicatie kunnen zjjn voor een van beide ziekten in engere zin. 
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Het aantonen van antimitocbonddale antistoffcn (AMA) en llon-purulente destructieve 
cholangitis bij een patient met cholestatische levcrfllncticstoornissen rechtvaardigt de 
diagnose PBC. Hiermee dient niet de diagnostische cvaillatic te wordcn bceindigd en 
cvclltuele bijkomende lever gerelateerde verschijnselen tc wardcll gCllcgccrd. Wanneer 
ernstige (icterische) hepatitis met hypergammaglobulinemie bij CCll PBC patient wordt 
gevandcn, moet stellig rekening gehouden worden met de mogelijkheid van een PBC-
autailllllluunhepatitis (AIH) overlap syndroom. Cholestatische icterus, vaak gepaard 
gaande lllet therapie-resistente jeuk en gewichtverlies, bij een nan-cirrotische PBC patient 
met cen normale eiwit leversynthese capaciteit kan wijzen ap prematuur ductapene PBe. 
Deze vadanten van reguliere PBC zOllden beschouwd kunnen worden als uitersten van het 
PBC spectrum. Bij het PBC-AIH overlap syndroom staat zawel klinisch, biochemisch als 
histologisch inflammatie van het (labulaire) leverparenchym ap de voorgrond. Bij de 
voortijdig ductopene PBC variant daarentegen bepaalt het crnstige interlobulaire 
galgangverlies het klinisch, biochemisch en histologisch beeld. 
Wanneer bij choiangiografie mllitipele galgangstricturcn en -dilataties worden 
gevollden dient niet alltomatisch de diagnose PSC te worden gesteld. De galboom heeft 
namelijk slechts een beperkt repertoire van reactie 1l10gelijkheden op een brced scala van 
lokale en systemische aandoeningen ter beschikking. Identieke chaiangiografische beeJden 
van scleroserende cholangitis kllnnen zowel bij PSC ais bij 'scleroserende pancreato-
cholangitis' ,vorden gevonden. Deze laatst genoell1de aandoening onderscheidt zich van 
PSC in engere zin doordat het voornall1elijk voorkoll1t bij mannen van middelbare leeftijd, 
ruet gepaard gaat met inflammatoire darmziekte en de initiele presentatie sterk lijkt op die 
van patienten met een pallcreascarcinoom. Naast systemische aandocningen, zoals onder 
andcre AIDS, 'graft-verslls-host' ziekte en systemische idiopathische fibrose, kllnnen 
lokale aandoeningen zoals trombose van de vena portae met cavernomateuze transfonnatie 
eveneens de oorzaak van scleroserende cholangitis zijn. Evenals bij PBC bestaat er bij PSC 
ook een overlap syndroom met AIH. Het PSC-AIH overlap syndroom lijkt in ongeveer 
10% van de PSC patientell poplliatie voor te komen en lijkt daarom minder zeldzaam dan 
voorheen werd gedacht. 
Deze verdergaande differentiatie van scleroserellde cholangitis en primaire biliaire 
cirrose is niet aileen wetenschappclijk gezien intcressant v<lImit het oogpunt van 
classificatie, maar heeft tevens duidelijke waarde voor bcslissingen betreffende 
behandcling en inschatting van de prognose van een individllele patient. De afwijkingen 
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passend bij sc1eroserende pallcreato-cholangitis lijken zeer goed te reageren op 
behandeling met prednison, terwijl PSC niet lijkt te responderen op deze behandeling. 
Andere medicamentellze behandelings opties voor PSC, zoals nicotine en budesonide, 
lijken de ziekte cvcnmin in gunstige zin te kunnen beYnvloeden. Wanneer er sprake is van 
een overlap syndroom met Am, zowel bij PSC als PBC, dient immunosuppressieve 
behandeling met prednison, eventllcel aangevllid met azathioprine, in principe gegeven te 
worden. Met name de Am component van deze ziektebeeldell kan hiennee worden 
onderdmkt. In tegenstelling tot 'reguliere' PBC lijkt de premature dllctopene variant van 
PBe gcen baat te hebben van behandcling met ursodeoxycholzllllf en immlillosuppressiva. 
Snell ere overweging van ievertransplantatie in verband lllet invaliderende therapie-
resistente jeuk en voorkoming van vcrdcrgaand gewichtsverlies, ondanks intacte lever 
eiwitsynthese en afwezigheid van cirrose, is bij deze categorie PBC patienten aangewezen. 
Een betrouwbare inschatting van dc prognosc van de ziekte is, naast het stcllen van cen 
diagnose die zoveel als mogelijk is afgestemd op het ziektebeeld van de individllele 
patient, eell ander beJangrijk aspect van de bebandeling van een immuuncholangitis 
patient. De mathematische prognostische modellen die ontwikkeld zijn door de Mayo 
Clinics kunnen slechts helpen bij de tinling van levertransplantatie aangezien de 
uitgangsvariabeien van deze modellen een uiting zijn van de ernst van de leverziektc. 
Verschi1lende factoren die onafilankelijk zijn van het stadium van PBC, zoals AMA-
profieien en AMA-titcrs, blijken helaas geen onderscheid te kunnen maken tussen 
patienten met een progressief of een relatief goedaardig ziektebeloop. Bij PSC is evenmin 
een prognostische factor, die onafhankelijk is van het ziektestadium, bekend. Het optreden 
van PSC-specifieke compJicaties, zoals een dominante galgangstenose, cholangitis of 
cholangiocarcinoom, tijdens het beloop van de ziekte blijkt cchter geassocieerd te Zijll met 
een slechtcre transplal1tatie-vrije overleving. 
Hopelijk zal toel1ame van ollze kennis van deze ziekten OilS in de toekomst in staat 
stellen een op de individuele immuuncholangitis patient toegespitste prognose te bepalen 
om eell op maat gesneden therapie te kUllnen instellen. 
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Erpecum en Jan van Hattum was erg prettig. Dc lcdcn van de beoordelingscol1l1nissic dank 
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